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Electrospray ionization was used in conjunction with Fourier-transform ion 
cyclotron resonance (FTICR) mass spectrometry and quadrupole ion trap (QIT) mass 
spectrometry to study protein and oligonucleotide ions in vacuo.  The results help to 
identify effective strategies for mass spectral analysis of these macromolecules and 
provide new insight on their gas-phase behavior.  
Tandem mass spectrometry experiments were conducted to evaluate different ion 
activation methods for biopolymer sequencing.  Multipole storage-assisted dissociation 
(MSAD) and sustained off-resonance irradiation collision-activated dissociation (SORI-
CAD) were compared for protein analysis in FTICR instrumentation, and infrared 
multiphoton dissociation (IRMPD) and collisonal activated dissociation (CAD) were 
compared for oligonucleotide analysis in QIT instrumentation.  In both studies, the 
differences in the observed fragmentation patterns were noted and the underlying reasons 
for these differences were identified.   The relative utility of MSAD vs. SORI-CAD and 
IRMPD vs. CAD were assessed in terms of their ability to produce diagnostic 
information that could be used to identify the protein or oligonucleotide under study. 
 vi
Tandem mass spectrometry was also employed to study the dissociation patterns 
of both DNA/metal and DNA/drug complexes.  The preferred fragmentation pathways 
exhibited by these species were observed to vary with the initial charge state of the 
precursor.  The effect of the oligonucleotide sequence, the identity of the metal ion, and 
the identity of the drug on these pathways was established and (where possible) 
interpreted in terms of the specific non-covalent bonding patterns present in the parent 
complexes. 
Finally, electrospray ionization was evaluated as a tool for screening molecular 
recognition in nucleic acid aptamer/small molecule interactions.  Gas-phase data for 
binding stoichiometry and relative binding affinity were compared with the known 
solution behavior for a series of well-characterized case studies.  Any observed 
discrepancies were rationalized in terms of ligand structure and/or the nature of the 
intermolecular ligand/aptamer interactions. 
 vii
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Chapter 1:  Introduction 
Life processes are driven at the molecular level by three major types of 
biopolymer: nucleic acids, proteins, and polysaccharides.  Each is comprised of small 
monomeric units (nucleotides, amino acids, or sugars, respectively) and the number, 
sequence, and arrangement of these individual components dictate the form and function 
of the composite macromolecule in vivo.  Detailed characterization of these biomolecules 
illuminates the mechanisms that propel replication, catalysis, and mutability, which are 
the hallmarks of living systems.1   
A broad range of techniques is available for chemical analysis of biopolymers, 
based on physical phenomena as simple as the action of centrifugal force on a mass 
(sedimentation) to spectroscopic phenomena as complex as surface plasmon resonance 
(SPR).  Mass spectrometry (MS), the analysis of ionic species in the gas phase,  is a 
relatively recent addition to this arsenal.  Biopolymers are large, polar molecules that 
would seem to be poorly suited to an analytical technique originally developed to study 
gases and small, volatile organic molecules.  Because of recent technological advances in 
ionization and mass analysis, however, the observation and/or characterization of intact 
biopolymers by mass spectrometry is now routine, and the speed, sensitivity, and 
specificity2,3 of mass spectrometric measurements can now be brought to bear on a 
number of fundamental questions in biochemistry and molecular biology.   
This chapter profiles the MS instrumentation most commonly employed to 
analyze biopolymers in the gas phase, then introduces two key applications of MS in the 
study of proteins and nucleic acids: analysis of primary sequence and analysis of non-
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covalently bound intermolecular complexes.  It ends with an outline of the following 
chapters, which describe original research in the analysis of proteins and nucleic acids by 
MS. 
 
1.1 INSTRUMENTATION FOR BIOPOLYMER ANALYSIS 
For decades biological macromolecules could not be analyzed by MS because the 
known ionization methods were too harsh to generate intact molecular ions.  By the 
1970s and early 1980s, however, several new techniques capable of producing molecular 
ions for small proteins and nucleic acids had emerged, including field desorption4,5 (FD), 
plasma desorption6-8 (PD), and fast atom bombardment9-11 (FAB).  These methods made 
it possible to detect mass spectrometric signals for proteins with molecular weights up to 
approximately 5 kD, but they were rarely effective for larger analytes.  However, the two 
critical breakthroughs in ionization methodology were made in the mid to late 1980s.  In 
1984 John Fenn interfaced electrospray ionization (ESI), a physical phenomenon reported 
years earlier,12,13 to a quadrupole mass filter,14 and in initial studies signals for proteins as 
large as conalbumin (76 kD) were generated with this new system.15  In 1989, Karas and 
Hillenkamp used a technique later named matrix-assisted laser desorption ionization 
(MALDI) to ionize proteins as large as bovine serum albumin (67 kD).16  A similar 
technique, reported at about the same time by Tanaka, produced gas phase ions for 
several proteins with the molecular weights ranging from 12 to 34 kD.17  The use of ESI 
and MALDI spread rapidly, and both methods have been shown capable of producing 
gas-phase ions from macromolecules with molecular weights in excess of 200 kD. 
Electrospray tends to produce multiply charged ions from analytes bearing more 
than one ionizable functional group, and even large proteins and nucleic acids therefore 
appear as an envelope of multiply charged ions at relatively low m/z regimes when 
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subjected to ESI.  Inexpensive, rugged quadrupole mass filters and quadrupole ion traps, 
which normally operate up to m/z 2000, can therefore provide effective mass analysis of 
electrosprayed protein and nucleic acid ions in many applications.  For additional mass 
range, ESI has been used in conjunction with time-of-flight (TOF) mass analysis, which 
can be effective up to m/z 350,000.  Modern  TOF instrumentation also offers improved 
mass resolution and accuracy relative to quadrupole systems, and to exploit this, a variety 
of hybrid TOF instrument platforms featuring a “front end” quadrupole mass filter,18 
quadrupole ion trap,19,20 or linear ion trap21,22 and a “back end” TOF mass analyzer have 
appeared.  For the most exacting applications, ESI is often used in conjunction with 
Fourier transform ion cyclotron resonance (FTICR) mass analyzers, which offer the best 
resolution and mass accuracy available.  To facilitate mixture analysis, ESI can be easily 
interfaced with techniques such as HPLC23 or CE,24,25 to provide “on-line” separation 
prior to mass analysis.  Even highly complex samples can be processed and analyzed in 
this way; in one benchmark example, over 400 different proteins from E. coli cell lysates 
were identified by experimentally determined molecular weights after capillary 
isoelectric focusing.26 
 In contrast with ESI, MALDI tends to produce singly charged species, and 
protein and nucleic acid ions generated by MALDI can therefore have m/z values well in 
excess of 10,000.  A mass analyzer with an inherently large range is needed to detect 
such species, so MALDI is most commonly used in conjunction with TOF 
instrumentation.  MALDI is quite robust for mixture analysis because it usually produces 
just one peak per analyte, and signals for individual proteins have been generated from 
samples as complex as biological tissue using MALDI.27  These signals reflect the 
analyte population at a small, specific location, so MALDI can be used in a rastering 
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mode to yield information about the spatial distribution and relative abundance of various 
proteins in normal vs. abnormal tissues.27   
 
1.2 BIOPOLYMER SEQUENCE ANALYSIS BY MS 
Mass spectrometry can offer a practical alternative to established wet chemistry 
protocols for determining the sequence of a nucleic acid or protein.  Mass spectrometry 
was first employed in sequencing efforts in the early 1960s, when Klaus Biemann 
performed chemical digestion of peptides and derivatized the resulting amino acids to 
yield volatile species suitable for analysis by GC/MS.28  Modern ionization technology 
produces intact multiresidue ions, so today gas-phase tandem mass spectrometry is 
usually employed to generate sequence information.  Many fundamental studies of 
peptide and oligonucleotide fragmentation have been conducted using several ion 
dissociation techniques,29,30 and standard fragment ion nomenclature systems for both 
peptide/protein31 and oligonucleotide32 dissociation have been devised (Figures 1.1 and 
1.2). In general, both peptides and oligonucleotides tend to fragment between residues, 
and selectivity for particular interresidue bonds (the amide bond of peptides and the 
ribose 3’-O-phosphate bond for oligonucleotides) increases as the amount of energy 
deposited into the parent decreases.  Small peptides and oligonucleotides often cleave at 
nearly every interresidue junction, so a fragment “ladder” can usually be constructed to 
retrieve the original sequence.  As molecular weight increases, however, sequencing 
becomes more difficult:  for peptides, sequence coverage tends to decrease and sequence 
information is therefore often incomplete, and for oligonucleotides, spectral complexity 
tends to increase and unambiguous data interpretation therefore becomes less likely.  For 
these reasons, complete protein and oligonucleotide sequences longer than approximately 













Figure 1.1: Fragmentation of peptides and proteins.  A) Standard fragment ion 
nomenclature.  Peptide fragments containing the N-terminus belong to the 
a/b/c series and fragments containing the C-terminus belong to the x/y/z 
series.  Low-energy activation promotes the formation of b and y ions.  B) 


















































Figure 1.2: Fragmentation of oligonucleotides.  A) Standard fragment ion nomenclature.  
Fragments containing the 5’-terminus belong to the a/b/c/d series and 
fragments containing the 3’-terminus belong to the w/x/y/z series.  Low-
energy activation promotes the formation of an-Bn and w ions.  Chemical 




















































a1 b1 c1 d1
w3 x3 y3 z3
a2 b2 c2 d2
w2 x2 y2 z2
a3 b3 c3 d3
w1 x1 y1 z1
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interesting to note, however, that a recently developed dissociation method, electron 
capture dissociation,33,34 has been shown to provide nearly complete sequence coverage 
of a 29 kD protein.35  This technique offers considerable promise for de novo sequencing 
but much development work remains to be done.) 
Partial sequence information acquired by MS can, however, be used to confirm an 
expected sequence prepared synthetically or enzymatically, or to help identify and 
characterize sequence variants that may result from the omission, replacement, or 
modification of individual residues.  In an important contemporary application, partial 
sequence data can also be used in conjunction with computerized sequence libraries to 
identify genomically encoded proteins from complex biological samples.  Two distinct 
strategies have developed to address this task.  In the “bottom up” approach, intact 
proteins are enzymatically digested to produce a mixture of smaller peptides, which 
dissociate far more easily.36,37  Molecular weight and fragmentation data acquired for 
these peptides are cross-referenced with sequence libraries, and if the volume and quality 
of data is sufficient the parent protein will emerge as a “hit.”  The alternative, more recent 
“top down” approach is to record MW data for the intact protein, then dissociate it 
directly and use the resulting mass and fragmentation data to search sequence 
libraries.38,39  This strategy requires high mass accuracy (generally provided by FTICR 
instrumentation) and different search algorithms,40 but it is far more likely to detect post-
translational modifications to the genomically encoded primary sequence.   
In recent years, both the “bottom up” and “top down” approaches have been 
integrated with separation techniques, electrospray ionization, and automated search 
algorithms to provide protein profiling of highly complicated systems.  To cite just one of 
dozens of recent examples, the bottom up approach provided identification of over 1900 
proteins from D. radiodurans, 715 of which had previously listed as hypothetical.41  The 
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top down approach is less mature, but significant progress in both front-end sample 
manipulation42 and back-end data processing40 has recently been reported.  Integrated 
approaches aiming to exploit the strengths of both strategies are also beginning to 
emerge.41,43 
 
1.3 MS FOR THE STUDY OF NON-COVALENT BIOMOLECULE INTERACTIONS 
Biopolymers function in vivo by specific intermolecular associations with metal 
cations, small molecules, and other biopolymers, and these associations can occur on 
either a transient basis (as for enzyme-substrate interactions) or a more permanent basis 
(as for interactions between protein subunits or strands of DNA).  Various aspects of 
these complexation processes can be studied by a number of solution techniques, 
including ultracentrifugation, microcalorimetry, surface plasmon resonance, and several 
different kinds of spectroscopy.  In addition, X-ray crystallography can provide detailed 
information about structure and conformation adopted by proteins and nucleic acids when 
they interact with other biomolecules. 
Over the last decade it has become clear that ESI-MS can also be used to study 
some non-covalent complexes formed in solution.3,44,45  Early in the development of ESI, 
it was recognized that using gentle ionization and interface conditions (i.e. low 
temperatures and voltages) non-covalent complexes involving both proteins46,47 and 
nucleic acids48-50 can be transferred intact from solution into the gas phase.  To generate 
and preserve these intermolecular interactions, however, the composition of electrospray 
samples must approximate physiological conditions.  Buffers containing either 
ammonium acetate or ammonium bicarbonate are often used in place of standard 
biological buffers containing involatile metal salts, which are more likely to suppress 
ionization and can clog the sampling orifice of the mass spectrometer.44  Organic co-
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solvents can strongly enhance ionization in electrospray experiments, but because they 
tend to denature proteins and disrupt intermolecular bonding, experiments involving non-
covalent protein complexes are usually conducted with strictly aqueous samples.44  
Interestingly, the intermolecular interactions of nucleic acids are more tolerant of (and 
may even be enhanced by) low proportions of some organic solvents,51 so to improve 
instrument response studies involving nucleic acids are typically performed with samples 
containing 10-50% acetonitrile, methanol, or isopropanol.51-57 
Using appropriate samples and instrument parameters, ESI produces intact gas-
phase complexes at stoichiometries and relative populations that can directly reflect 
solution binding properties.  ESI mass spectra have been used to observe the subunit 
composition of multimeric proteins,3 distinguish between duplex, triplex, and quaduplex 
DNA,58,59  and observe characteristic drug/receptor binding stoichiometries.52,56,57,60  The 
relative peak intensities observed for complexes between a given receptor and various 
ligands can reflect relative binding affinities observed in solution,52,61 and this type of 
analysis has been implemented in high-throughput drug discovery platforms.62-64  In 
addition, absolute binding constants have been accurately determined by MS via titration 
experiments that relate the mass spectral peak intensity for an intact complex with ligand 
concentration.60,65,66  In gas-phase dissociation experiments, the activation energy 
required to cleave non-covalent protein and nucleic acid complexes can correlate with 
solution binding affinity.54,67-70 
However, gas-phase data for non-covalent complexes can at times present a 
misleading picture of solution binding processes.  In some reports, the relative signal 
intensities71 and dissociation energetics72,73 observed in MS experiments with 
receptor/ligand complexes have provided relative binding trends that disagree with 
known solution behavior.  Such results likely indicate that the relative influence of 
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electrostatic and hydrophobic interactions is different in vacuo than in solution, a notion 
which merits additional study in future research. 
 
1.4 OVERVIEW OF CHAPTERS 
Chapter 2 describes general experimental procedures employed in this research, 
including methods for sample preparation, ionization, and mass analysis.  The subsequent 
chapters describe results obtained in gas-phase studies of the dissociation of intact 
proteins, nucleic acids, and certain non-covalent complexes of nucleic acids, as well as 
the association of nucleic acids with small molecule ligands. 
In Chapter 3, two dissociation methods, sustained off-resonance collision-
activated dissociation (SORI-CAD) and multipole storage-assisted dissociation (MSAD),  
are compared for the analysis of intact proteins in the FTICR.  Because of non-resonant 
activation and mass discrimination effects, MSAD spectra often appeared quite distinct 
from SORI-CAD spectra. However, both techniques provided fragmentation information 
that allowed positive identification of the parent proteins in online database searches.  
Chapter 4 describes a comparison of infrared multiphoton dissociation (IRMPD) and 
collision-activated dissociation (CAD) for nucleic acid analysis in a quadrupole ion trap.  
The results showed that sequence information derived by these techniques was 
comparable in many respects.  Diagnostic low mass ions not visible in CAD spectra 
could be observed in IRMPD spectra, however, and for this reason the use of IRMPD can 
sometimes facilitate identification of modified nucleobases.   
Chapter 5 describes the dissociation patterns observed for a series of 
oligonucleotide/metal complexes in the quadrupole ion trap.  Fragmentation data for low 
charge state precursors indicated that metal complexation may alter the gas-phase 
conformation of the oligonucleotide.  Unusual fragment ions were observed for some 
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high charge state precursors, indicating that metal complexation may promote 
deprotonation of some nucleobase moieties.  In Chapter 6, the influence of the initial 
charge state on fragmentation patterns for drug/DNA complexes is examined.  Duplex 
strand separation predominated for higher charge states regardless of drug binding mode, 
while for lower charge states loss of ligand was more likely for intercalators and covalent 
cleavage was more likely for minor groove binders.  The dissociation pathways for the 
lower charge state complexes are probably more reflective of specific drug-DNA 
interactions.   
And finally, Chapter 7 describes non-covalent interactions of nucleic acid 
aptamers with their cognate small molecule ligands in the gas phase.  The results indicate 
that the gas-phase data for aptamer/ligand complexes reflect the solution phase behavior 
in only some respects.  Discrepancies were most likely to arise for complexes maintained 
in solution by significant π-stacking interactions. 
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Chapter 2:  Experimental Overview 
The experiments described herein were performed using electrospray ionization 
and commercially available FTICR or QIT instrumentation.  FTICR instruments are 
known for their high resolution and high mass accuracy capabilities, whereas QIT mass 
spectrometers offer a high degree of ruggedness and sensitivity.  An IonSpec HiResESI 
FTICR, located at Oak Ridge National Laboratory, was equipped with a 9.4T magnet and 
allowed the comparison of two ion fragmentation methods, sustained off resonance 
irradiation collision-activated dissociation (SORI-CAD)1 and multipole storage-assisted 
dissociation (MSAD)2 for analysis of intact proteins.  A Hitachi 3DQ QIT mass 
spectrometer was modified for infrared multiphoton dissociation (IRMPD)3 and thus 
allowed an assessment of IRMPD for fragmentation of oligonucleotide anions in the 
quadrupole ion trap.  A ThermoQuest LCQ Duo QIT system was used to study 
dissociation of oligonucleotide/metal complexes, drug/duplex DNA interactions, and 
small molecule/nucleic acid aptamer interactions.  Brief descriptions of the major 
techniques employed in these studies are provided below. 
 
2.1 ELECTROSPRAY IONIZATION (ESI) 
Electrospray ionization4 generates gas-phase ions directly from liquid samples, 
and has been widely implemented in mass spectrometric investigations of biomolecules 
as well as an enormous variety of other analytes.5  In a typical electrospray experiment 
(refer to Figure 2.1), the sample solution is infused through a capillary held at high 



















































droplets rapidly produce ions that enter the vacuum region of the mass spectrometer 
through a small sampling orifice.  Heated elements in the front end of the mass 
spectrometer assist the desolvation process (a heated capillary is shown in Figure 2.1, but 
heated lens assemblies can also be implemented).  Ions are then transferred through an 
ion optics region to the mass analyzer. 
In these studies, electrospray samples contained a protein or oligonucleotide at 
concentrations of 2 x 10-6 to 2 x10-5 M in a mixed aqueous/organic solvent (10-50% 
acetonitrile, methanol, or isopropanol).  Samples used to study non-covalent gas-phase 
complexes of oligonucleotides also contained secondary analytes, such as metal ions 
and/or “guest” molecules, in modest proportion.  Various additives, such as acetic acid, 
the combination of piperidine and imidazole, or ammonium acetate were also employed 
as needed to promote ionization.  The resulting samples were introduced to an 
electrospray source by continuous infusion at 1-5 µl/min.  ESI needle voltages were 
typically +3.5 kV for detection of protein ions in positive mode and –2 to –4 kV for 
detection of oligonucleotide ions or complexes in negative mode. 
In FTICR experiments using the IonSpec instrument (Figure 2.2), ions were 
accumulated in the optics region and periodically transferred to the ICR cell (typically 2 x 
10-10 Torr).  In QIT experiments ions were accumulated in the mass analyzer itself.  
Typical operating pressures were 3.5 x 10-5 Torr for the Hitachi instrument and 1 x 10-5 
Torr for the ThermoQuest instrument (Figure 2.3).  Both QIT systems employed a buffer 
gas (He) to facilitate trapping and resonant ejection. 




















Figure 2.3: Schematic diagram of the ThermoQuest LCQ Duo QIT mass spectrometer. 































vacuum chamber (ca. 1 x 10-5 Torr)
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2.2 ION DISSOCIATION AND MASS ANALYSIS 
2.2.1 Collision-Activated Dissociation (CAD) 
Collision-activated dissociation is a process by which energetic collisions with 
neutral molecules cause ion fragmentation, and is the most widely used method for 
structural characterization of gas-phase ions.  In this research CAD experiments were 
conducted on both FTICR and QIT instrumentation.   
A common variant of CAD, sustained off-resonance irradiation (SORI-) CAD 
was performed in the FTICR mass spectrometer.  In this technique, non-resonant 
waveforms excite trapped ions to encourage collisions with a neutral target gas.  In the 
studies described herein, precursor ions trapped in the cell were isolated with stored 
waveform inverse Fourier transform (SWIFT) pulses, and excitation waveforms were 
then applied at a frequency 1 kHz lower than the ion cyclotron frequency of the isolated 
precursor.  The collision gas (N2) was admitted to a transient pressure of 5 x 10-6 Torr in 
synchronization with the excitation waveforms.  After a 10s pump down delay, mass 
analysis was achieved by broadband excitation/detection.6 
Standard CAD was performed with resonant excitation waveforms in the QIT 
mass spectrometer.  Precursor ion isolation was achieved by applying either broadband 
axial waveforms or by DC/RF voltages.  Ion activation was then achieved by applying 
resonant frequencies across the end-cap electrodes for 30-50 ms to promote energetic 
collisions with the background gas (He).  Throughout the experiment the voltage on the 
ring electrode was maintained to provide a q value of about 0.3.  Under these conditions 
the lower mass range is truncated at an m/z value that is about 1/3 of the precursor ion.  
After the dissociation period, fragment ions were detected by mass-selective axial 
instability ejection with axial modulation.7 
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2.2.2 Multipole Storage-Assisted Dissociation (MSAD) 
In MSAD, space charge-mediated dissociation occurs in the linear RF-only 
multipoles commonly used to interface electrospray ionization with FTICR cells.  This 
method is a form of CAD2,8,9 that provides efficient but non-resonant (i.e. not mass 
selective) activation.  In MSAD experiments, electrosprayed ions were allowed to 
accumulate in the hexapole region of the IonSpec FTICR mass spectrometer.  To 
encourage dissociation a DC offset was applied to the hexapole during accumulation.  An 
electrostatic lens was then used in conjunction with a mechanical shutter to transfer the 
resulting ion population through the high vacuum region and into the cell, and mass 
analysis was performed by broadband excitation/detection. 
 
2.2.3 Infrared Multiphoton Dissociation (IRMPD) 
IRMPD is an alternative to CAD in which irradiation of trapped ions with infrared 
photons leads to vibrational excitation and ion dissociation.  The commercially available 
Hitachi 3DQ system was modified in house to allow IRMPD experiments (Figure 2.4).  
The vacuum chamber was customized to position an IR-transparent ZnSe window (II-VI 
Inc.) directly over the ion trap, and a 6-mm hole was drilled through one side of the ring 
electrode.  The beam from a continuous CO2 laser (Synrad, Inc.) was directed through the 
ZnSe optic and into the center of the trap, and TTL pulses supplied by the 3DQ software 
were used to power the laser on and off at appropriate intervals.  In addition, external DC 
inputs were applied to allow DC/RF isolation,7 which provides greater ejection efficiency 






























In IRMPD experiments, ions isolated by DC/RF were activated by CO2 laser 
irradiation.  To allow detection of characteristic small fragment ions, the RF trapping 
voltage was adjusted to establish a low mass cutoff at m/z 70 during the ion activation 
period.  After the dissociation period, fragment ions were detected by mass-selective 
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Chapter 3:  Comparison of SORI-CAD and MSAD for Top-Down 
Protein Analysis 
3.1 INTRODUCTION 
Mass spectrometry (MS) has played a critical role in the rapid advance of 
proteomics research.1  Protein samples are often analyzed using a “bottom-up” approach, 
which typically involves one- or two-dimensional chromatography or electrophoresis, 
proteolytic digestion of the resulting fractions, and mass spectrometric fingerprinting of 
component peptides.2-4  Tandem mass spectrometry is sometimes performed to provide a 
more thorough analysis of particularly complex protein mixtures.5-7 However, the 
enzymatic digestion process central to the bottom-up approach not only complicates 
sample handling but also generates large quantities of data that can be difficult and time-
consuming to process.  In addition, valuable information about post-translational 
modifications to the sequence encoded by the genome can be lost because intact protein 
masses are not determined. 
An alternative “top-down” strategy eliminates the digestion process and instead 
involves direct MS/MS analysis of intact proteins.8-10  In this approach, primary sequence 
information derives exclusively from fragmentation patterns, so robust ion activation 
techniques are critical.  The most effective methods of protein fragmentation include 
sustained off-resonance irradiation collision-activated dissociation (SORI-CAD),11,12 
nozzle-skimmer dissociation (NS),13,14 infrared multiphoton dissociation (IRMPD),15 and 
electron capture dissociation (ECD).16-18  In a recent report CAD, IRMPD, and ECD were 
used in combination to provide backbone coverage sufficient to establish the primary 
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sequence(s) of several proteins using MS data alone.19  In most applications, however, 
fragmentation data would be used to query a database of known sequences to identify any 
previously characterized proteins that may be present in a sample of unknown 
composition.  In several studies the sequence tag construct identified by Mann et al.20 has 
been shown to be an effective tool in this process.21-24  In other recent reports it has been 
demonstrated that existing databases can be queried with unprocessed product ion data in 
conjunction with experimental molecular masses.25,26  This approach provides flexibility 
in situations where sequence tags are either not observed or provide insufficient data for 
unambiguous identification, and online access to this search strategy has recently become 
available.27 
To date top-down protein analysis has largely been restricted to infusion 
experiments, in which analyte concentrations are constant.  In a variety of applications, 
such as LCMS or high-throughput protein array analysis techniques under current 
development at ORNL,28 analytical signals are transient in nature.  Fourier-transform ion 
cyclotron resonance (FTICR) platforms offer excellent resolution and mass range 
capabilities in such applications.  However, certain dissociation methods available in 
FTICR instruments, such as SORI and ECD, possess relatively low duty cycles, and 
significant portions of a transient signal profile may be poorly sampled.  IRMPD offers a 
relatively high duty cycle, and was successfully incorporated by Li et al. in the LC-FTMS 
analysis of a mixture of intact proteins.29  
Another efficient but less well-characterized method of ion dissociation is 
multipole storage assisted dissociation (MSAD).30 In this technique, space charge-
mediated dissociation occurs in  the linear RF-only multipoles commonly used to 
interface electrospray ionization with FTICR cells.  Under certain conditions (extended 
accumulation times and/or  larger dc offset voltages), ion activation and dissociation can 
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be induced during the ion accumulation interval in an inherently high-pressure region of 
the instrument, so no pump-down periods are required and the overall duty cycle is quite 
high.  Linear ion traps are often used to interface electrospray ionization with FTICR 
cells, so MSAD can be readily performed on many FTICR instruments with no additional 
components.  Sannes-Lowery et al.31 and Hakansson et al.32 demonstrated that MSAD is 
fundamentally a collisionally activated process, which implies that MSAD could in 
theory access the same fragmentation pathways as more established collisional activation 
methods like SORI.  Hakansson et al.32 compared MSAD and SORI for the 3 kD peptide 
melittin and found that the resulting spectra were indeed quite similar.  It is not clear, 
however, how these two methods compare for larger proteins, which tend to produce 
broader charge state distributions upon electrospray ionization.  In contrast with SORI, 
where individual charge states would typically be isolated and dissociated separately, 
MSAD activates the entire ensemble simultaneously.  Contributions from distinct 
fragmentation pathways are therefore more likely in MSAD experiments, and because 
protein dissociation patterns are known to be charge state dependent33-35somewhat 
different fragmentation information could therefore result.  For this reason a systematic 
comparison of SORI and MSAD was undertaken for a variety of 8-18 kDa proteins, with 
particular emphasis on the relative ability of these methods to provide fragmentation 
information that can be used in database search strategies for the positive identification of 
the parent proteins. 
 
3.2 EXPERIMENTAL 
Bovine ubiquitin and bovine β-lactoglobulin A were acquired from Sigma and 
used with no additional purification.  Recombinant TNF-α (mouse and human), IL-2 
(human), IL-3 (human), and IFN-γ (mouse, rat, and human) were acquired from 
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PeproTech Inc. (Rocky Hill, NJ) and reconstituted according to manufacturer’s 
recommendations.  Samples for mass spectrometry were prepared at formal 
concentrations of 5-10 µM in 50:50:1 (v/v/v) acetonitrile:water:acetic acid.  Mouse and 
human IFN-γ were desalted using C4 ZipTips (Millipore, Bedford, MA) prior to dilution.  
Mass analysis was performed with a HiResESI Fourier-transform ion cyclotron 
resonance mass spectrometer (IonSpec, Lake Forest, CA) equipped with a 9.4T magnet 
(Cryomagnetics Inc., Oak Ridge, TN).  Samples were introduced to an electrospray 
interface (Analytica of Branford, CT) by infusion at 1-3 µl/min.  Ions were accumulated 
in an external hexapole situated between the skimmer cone on one end and an exit lens 
and mechanical shutter on the other (diagram, Figure 3.1).  The pressure in this region of 
the instrument was typically around 2 x 10-5 Torr.  At the end of the accumulation period, 
the exit lens voltage was dropped to zero and the mechanical shutter was pulsed open to 
allow ion transfer to the ICR cell.  In SORI experiments, ion accumulation (typically 300 
to 1200ms) was followed by a short period (130ms) for ion isolation, which was 
accomplished with a SWIFT pulse.  Activation (1-4 Vp-p, 1s) was performed at a 
frequency 1 kHz lower than the parent ion cyclotron frequency in the presence of 
nitrogen, which was admitted with a pulsed valve to a transient pressure of 5 x 10-6 Torr.  
An 8-10 s pump-down delay was inserted prior to detection to produce overall scan 
functions of 12-15 s per transient.  For MSAD experiments simultaneous ion 
accumulation/activation was usually performed for 500 to 4000 ms at a hexapole offset 
voltage of –8V (Fig. 3.1).  This creates a deeper potential well than the standard offset 
setting (-3.5V) and therefore promotes ion fragmentation during the accumulation 
period.36 Discrete isolation, activation, or pump-down delay times were not necessary, so 







Scan Function Step Time (ms) Skimmer (V)
Hexapole 




parameters 300-1200 +10 -3.5 +4.5 -20 
 MSAD parameters 500-4000 +10 -8 +4.5 -20 
Ion injection  160 +10 0 0 -20 
 
Figure 3.1: Schematic diagram of the hexapole accumulation region of the HiResESI 











Each spectrum was comprised of ten coadded transients acquired at 512K data 
points/transient, and external calibration was performed with ubiquitin; these conditions 
typically result in mass accuracy of ± 5 ppm and resolution of 150,000 (FWHM).  
Product ion spectra were deconvoluted to zero charge state with the IonSpec software 
deconvolution tool, and sequence tags were identified by manual inspection of the 
deconvoluted spectra.  Product ion assignments were then made by comparison with 
theoretical isotopic distributions generated by the IonSpec exact mass calculator. 
Database searches using the sequence tag strategy were performed using the 
TagIdent tool of the ExPASy molecular biology server.37 For each protein the Swiss-
PROT and TrEMBL databases were queried with experimentally determined molecular 
mass and sequence tag information.  To facilitate identification of post-translationally 
modified proteins, a search tolerance of ± 500 Da was allowed for molecular mass data.  
The TagIdent tool restricts sequence tag entries to a maximum of six residues; in cases 
where longer tags were obtained, six residue subsequences containing a minimum 
number of ambiguous residues were chosen.  All sequence tags were submitted in both 
the forward and reverse directions, and no keyword, species, or pI constraints were 
imposed.   
 
3.3 RESULTS AND DISCUSSION 
3.3.1 Fragmentation Patterns Determined by MSAD and SORI  
Dissociation results obtained in MSAD experiments at various accumulation 
times were compared with data from SORI activation of 4-7 different charge states of 
each protein.  In a few cases, the two dissociation methods gave very similar results.  For 
other proteins, however, distinct differences between the MSAD and SORI data were 
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evident.  Several factors that appear to create or contribute to spectral differences 
between MSAD and SORI spectra were identified. 
Charge State Distribution:  MSAD and SORI data for bovine ubiquitin are 
presented in Figure 3.2.  Standard electrospray conditions (hexapole offset = -3.5 V) 
produced a charge state distribution dominated by the +10 to +12 charge states as shown 
in Fig. 3.2A.  Under MSAD conditions (hexapole offset = -8V) an accumulation time of 
1250 ms produced significant dissociation of the intact protein and gave a spectrum 
dominated by the y58, y24, and y18 ions (Fig. 3.2B, C).  These results are qualitatively 
similar to data reported by Sannes-Lowery et al.,30 who inferred that the dominance of 
just a few dissociation channels was observed because MSAD intrinsically selects for the 
lowest energy processes.  However, direct comparison of MSAD and SORI data for this 
protein suggests that charge state dependent fragmentation may be another possible 
explanation.  The major species in Fig. 3.2A (the +10 to +12 ions) gave relatively narrow 
product ion distributions in SORI experiments as illustrated by data for the +10 ion (Fig. 
3.2D).  This is consistent with previously reported results obtained by CAD in a 
quadrupole ion trap.33    In contrast, the intermediate charge states (the +7 to +9 ions) 
gave a greater variety of fragments, as illustrated by the SORI spectrum of the +8 ion 
(Fig. 3.2E).  These ions carry less overall charge, so proton mobility along the amide 
backbone is increased and a wider array of products results.33  Fig. 3.2B indicates that the 
MSAD experiment consumed essentially the entire population of the +10 and +11 charge 
states, while detectable levels of the intermediate charge states (+7 to +9) survived.  In 
addition, a comparison of Figs. 3.2C-E illustrates that MSAD produced results far more 
similar to SORI of the +10 ion than SORI of the +8 ion.  These observations suggest that 
spectra generated by MSAD may simply reflect the different fragmentation tendencies of 






















Figure 3.2: Dissociation data for bovine ubiquitin.  A) Positive ion ESI mass spectrum, 
750 ms accumulation, hexapole offset –3.5V.  B) MSAD, 1250 ms 
accumulation, hexapole offset –8V.  C) MSAD, 1250 ms accumulation, 
deconvoluted to zero charge state.  The large peak for intact ubiquitin 
resulted from non-uniform actiationof the original charge state envelope 
(vide infra).  D) SORI, +10 charge state (deconv).  E) SORI, +8 charge state 
(deconv).  Asterisks denote standard b/y fragments that have undergone loss 








1400600 800 1000 1200 1600400
B)

























































states in Fig. 3.2A gave less overall sequence coverage and less sequence tag information 
(see below) than collective SORI results for the +7 to +12 charge states.  This apparent 
charge state dependence implies that in infusion experiments it may be possible to tune 
MSAD for particular fragmentation channels by manipulating parameters that affect the 
observed charge state distribution, such as the composition and pH of the electrospray 
solvent. 
Radial Stratification:  MSAD spectra acquired for recombinant mouse interferon-γ 
after 1000 and 2600 ms accumulation periods are shown in Figure 3.3A-C, and the SORI 
spectrum obtained from the +15 charge state is shown in Figure 3.3D.  Similar N-
terminal sequence tags (y114-y120 and y115-y121) dominate the product ion 
distributions in both Fig. 3.3C and D, which suggests that energy distribution in MSAD 
and SORI can be quite comparable.  This is reflected in the fact that both activation 
methods produced approximately the same sequence coverage and sequence tag data for 
this particular protein. 
In SORI experiments, the activation voltages required for 70% conversion of 
parent to backbone cleavage products followed the trend +17 < +16 < +15 < +14.  
However, Figure 3.3B shows that MSAD preferentially consumed the lowest charge 
states first. This behavior was also observed in MSAD of multiply charged peptides by 
Smith et al., who demonstrated with theoretical calculations that high m/z species tend to 
adopt larger radial orbits in linear ion traps.36,38 This radial stratification results in greater 
average kinetic energies at the outer portions of the ion cloud.  As accumulation time 
increases, increasing space charge within the linear trap causes the ion cloud to expand 
radially, increasing the likelihood that high m/z species (i.e. the lower charge states) will 
dissociate upon collision with background neutrals.  Non-uniform activation can 
therefore  supersede intrinsic trends in  dissociation thresholds across a given charge state  
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Figure 3.3: Dissociation data for mouse IFN-γ.  A) Positive ion ESI mass spectrum, 
1000 ms accumulation, hexapole offset –8V.  Peaks corresponding to a 
minor sequence variant contaminating the sample are marked (*).  B) 
MSAD, 2600 ms accumulation (deconv).  D) SORI, +15 charge state 
(deconv).  Asterisks denote standard b/y fragments that have undergone loss 
of ammonia or water. 









































distribution.  MSAD spectra for most proteins investigated in this study showed some 
evidence of this phenomenon. 
In the case of mouse IFN-γ, radial stratification had little impact on the 
fragmentation patterns observed by MSAD relative to those from SORI experiments.  A 
distinct impact was observed in the dissociation data for other proteins, however.  MSAD 
data acquired for horse apomyoglobin after accumulation periods of 750, 1000, and 2000 
ms is presented in Figure 3.4.  A comparison of Figs. 3.4A-C illustrates the tendency of 
MSAD to reduce overall charge density and compress ion signal into the low m/z region 
of the spectrum.  At the 750 ms time point a broad charge state envelope was observed, 
but after 1000 ms the charge state distribution was much narrower and only a modest 
amount of dissociation is evident.  This suggests that because of radial stratification 
within the hexapole, increasing space charge either propelled the lowest charge states to 
radii that exceed that of the conductance limit (exit lens, Fig. 3.1), or led to ejection rather 
than dissociation of the lower charge states.  Among the species lost were the 
“intermediate” charge states (+12 to +14), which have been shown to provide the widest 
variety of fragment ions,34 and as for ubiquitin the overall sequence coverage and 
sequence tag data retrieved for this protein by MSAD suffered as a result. 
While radial stratification seems to have been responsible for premature loss of a 
several parent ions for apomyoglobin, product ion information seems to have been 
compromised for human TNF-α.  SORI and MSAD data for this protein are presented in 
Figures 3.5 and 3.6, respectively.  SORI of the +14 charge state (Fig. 3.5A and B) 
produced a spectrum dominated by the y138 and y136 species, in addition to a 7-residue 
sequence tag comprised of the b149-156 ions. MSAD consumed most of the +14 charge 





Figure 3.4:  Spectra acquired for horse apomyoglobin under MSAD conditions 
(hexapole offset = -8 V).  A) 750 ms accumulation, B) 1000 ms 

































Figure 3.5: Dissociation data for human TNF-α.  A) SORI, +14 charge state, B) SORI, 
+14 charge state (deconv.), C) Positive ion ESI spectrum, 1200 ms, 
hexapole offset –8V, D) 3750 ms accum., E) 3750 ms accum. (deconv.)  
























Figure 3.6: Dissociation data for human TNF-α.  A) Positive ion ESI spectrum, 1200 
ms, hexapole offset –8V, B) 3750 ms accum., C) 3750 ms accum. (deconv.)  
Asterisks denote standard b/y fragments that have undergone loss of water 
or ammonia. 
 






































recovered and the y138 and y136 ions were missing entirely.  These fragments constitute 
a major dissociation pathway so it seems unlikely that differences in energy distribution 
in the SORI and MSAD experiments would account for this result.  However, in Fig. 
3.5A it can be seen that the missing y ions form in the high m/z region of the spectrum.  It 
is possible that in the MSAD experiment these fragment ions adopt radii that exceed the 
radius of the conductance limit in the optics region and are therefore not transferred to the 
cell for mass analysis.  It is also possible that at high space charge the effective potential 
well is too shallow to trap high m/z fragments.  Either of these explanations may also 
account for the fact that the b149 and b151-155 ions that help define the sequence tag in 
Fig. 3.5B do not appear in Figs. 3.6B and C. 
Non-Resonant Activation:  SORI and MSAD data for mouse TNF-α are presented 
in Figure 3.7 and 3.8.  SORI of the +12 charge state produced a wide variety of fragment 
ions, including an extended sequence tag comprised of the b142-b152 and b154-b156 
ions (Figs. 3.7A-C) along with several complementary ions (y6-y8 and y11-y12) at low 
intensity.  At moderate accumulation times (Figs. 3.8B-C), MSAD produced only some 
of the b ions comprising the sequence tag, and those ions that do appear derive from 
dissociation of the +13 charge state.  The +12 charge state was completely consumed, 
however, and comparison with Fig. 3.7A suggests that, again, trapping and/or 
transmission of high m/z ions may have been impaired under conditions of high space 
charge and the b144-151+11 and b142-146+10 ion series were therefore not observed.  
Another difference between the Figs. 3.7B and 3.8C is that the complementary y ions 
were observed in higher signal intensity as an intact sequence tag in the MSAD 
experiment.  The improved response for these species by MSAD could be due to 
relatively poor trapping of low m/z species in the SORI experiment, relatively efficient 
trapping of low m/z species in the accumulation hexapole, or both.   
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Figure 3.7: SORI data for mouse TNF-α.  A) SORI, +12 charge state, B) +12 charge 
state (deconv.), C) Expansion of sequence tag (deconv.).  Asterisks denote 
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Figure 3.8: MSAD data for mouse TNF-α.  A) Positive ion ESI mass spectrum, 1000 
ms accumulation, hexapole offset = -8V, B) MSAD, 2000 ms accumulation, C) MSAD, 
2000 ms accumulation (deconv.), D) MSAD, 3000 ms accumulation, and E) MSAD, 
3000 ms accumulation (deconv.).  Asterisks denote standard b/y fragments that have 
undergone loss of ammonia or water.





















































At longer MSAD times (Figs. 3.8D-E), a number of smaller ions defining two 
sequence tags (b48-b51 and b33-b39, corresponding to the sequences PVV(I/L) and 
A(N/D)A(I/L)(I/L)A) were observed.  These fragments form by secondary dissociation of 
the larger b ions found in Figs. 3.8B and C, and correspond to the loss of a portion of the 
amide backbone constrained by this protein’s single disulfide bond (C70-C101).  Only 
two of the ions comprising these additional sequence tags were observed in SORI 
experiments.  Because of the non-resonant nature of activation, MSAD provided better 
access to such secondary dissociation processes for this protein, and as a result MSAD 
produced greater sequence coverage and more sequence tags than SORI in this case. 
 
3.3.2 Comparison of Database Search Information Generated by SORI and 
MSAD  
Tables 3.1 and 3.2 summarize the dissociation data obtained by SORI and MSAD, 
respectively.  For each activation method, the observed sequence tags and corresponding 
fragment ion assignments are listed, along with the number of unique proteins (“hits”) 
retrieved from the ExPASy molecular biology server for each sequence tag.  The tables 
illustrate that all proteins in this study produced sequence tags by SORI, and that at least 
some sequence tag data can also be retrieved by MSAD.  For mouse IFN-γ, human IL-3, 
and human IL-2, the sequence tag data provided by the two activation methods was 
nearly the same.  For ubiquitin and apomyoglobin, however, it appears that charge state 
availability imposed by either the electrospray conditions or the effects of radial 
stratification restricted the level of fragmentation data observed by MSAD and therefore 
prevented identification of the parent protein.  For human TNF-α, mouse TNF-α, and β-
lactoglobulin A, the effects of radial stratification in MSAD disrupted the primary 
sequence tag seen in SORI experiments but also allowed trapping of a complementary
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Table 3.1: Fragmentation Data, SORI Experiments 
Sequence Tags 
Protein (MW) 






















7 of 8 
Human IL-3 
(15.1 kD) (I/L)S(I/L)A(I/L) b128*-b133* +13 75 hits 1 of 15 
Mouse IFN-γ 
(15.1 kD) ES(I/L)NNY y115-y121 +15, +16 1 hit
3 (correct) 0 of 8 
Human IL-2 
(15.5 kD) TFA(K/Q)S(I/L)(I/L) b123-b130 +14 0 hits
4 1 of 8 










--- 4 of 11 
Human TNF-α 
(17.4 kD) VYFG(I/L)(I/L)A b149-b156 +14 16 hits






b154-156 +12 14 hits
2 4 of 17 
β-Lactoglobulin A 
(18.3 kD) AMAASDIS(I/L)(I/L)DA(K/Q)SA y125-y140 +16 11 hits
2 4 of 19 
1Asterisks denote standard b/y fragments that have undergone loss of ammonia or water. 
2All hits were homologs of the correct protein. 
3Search constraints: sequence tag, MW ± 750 Da. 
4The correct database entry was not retrieved because of an amino acid substitution (C  A) within the sequence tag. 
5Most hits were homologs of the correct protein. 
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Table 3.2: Fragmentation Data, MSAD Experiments 
Sequence Tags 
Protein (MW) 


















7 of 8 
Human IL-3 
(15.1 kD) SNA(I/L)F b128*-133* 2500 0 hits
6 3 of 15 
Mouse IFN-γ 
(15.1 kD) (S/F/Y)(I/L)NNYF y114-120 3000 1 hit
3 (correct) 2 of 8 
Human IL-2 
(15.5 kD) TFA(K/Q)S(I/L)(I/L) b123-130 2750 0 hits
4 1 of 8 













































--- 2 of 19 
1Asterisks denote standard b/y fragments that have undergone loss of ammonia or water. 
2All hits were homologs of the correct protein. 
3Search constraints: sequence tag, MW ± 750 Da. 
4The correct database entry was not retrieved because of an amino acid substitution (C  A) within the sequence tag. 
5Most hits were homologs of the correct protein. 
6Insufficient sampling produced distorted isotopic distributions for some fragments comprising the sequence tag.  One residue (N) was therefore 
incorrectly identified and the correct database entry could not be retrieved
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ion series that provided information about the same portion of the amide backbone.  
Additional sequence tag information was also generated through secondary dissociation 
processes.  For mouse TNF-α and β-lactoglobulin A positive identification of the parent 
protein was therefore still possible. 
Tables 3.1 and 3.2 also list the number of “preferred” sites34 (N-terminal to 
prolines and C-terminal to aspartic acids) where backbone cleavage was observed for 
each protein.  This data illustrates that although sequence tag data was in some cases 
compromised by MSAD, cleavage at “preferred” sites was observed at least as often in 
MSAD as in SORI experiments.  Search algorithms that utilize raw mass data provide 
alternatives to the sequence tag approach,25,26 and typically weight fragments derived 
from cleavage at “preferred” sites more heavily than other fragments.  MSAD data might 
therefore be utilized more effectively within the framework of this newer type of search 
strategy.  In addition, because lower charge states can be lost during MSAD, algorithms 
that weight preferred cleavages associated with these parent ions less heavily than those 
associated with higher charge states could be advantageous. 
 
3.4 CONCLUSIONS 
MSAD spectra of intact proteins are influenced by several factors.  Data for 
bovine ubiquitin suggests that because dissociation patterns are charge state dependent, 
the charge state distribution made available by the ionization conditions may dictate the 
range of fragment ions that can be generated during the experiment.  In addition, 
conditions of high space charge within the hexapole impair transmission and/or trapping 
of high m/z species, which can result in loss of important precursor and product ions.  
And finally, the non-resonant nature of activation in MSAD can provide access to 
secondary dissociation processes that are not available by SORI.  Because of these 
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considerations, the two activation methods do not always provide the same fragmentation 
information, and MSAD is somewhat less reliable for generating sequence tag data.  
However, it appears that in general MSAD samples “preferred” cleavage processes (i.e. 
those occurring at D and P residues) just as well as SORI, which implies that MSAD data 
may be somewhat more compatible with search algorithms that utilize unprocessed 
fragment ion masses.   
Because MSAD scan functions do not require extended pump-down delays or 
discrete ion isolation and activation periods, individual MSAD experiments in this study 
required one-sixth to one-half the time needed for SORI experiments.  MSAD further 
reduced overall analysis time in that, unlike SORI, it was not necessary to select and 
dissociate an array of different charge states in order to characterize a given protein.  It 
remains to be seen, however, if these advantages can be exploited in the analysis of 
transient signals.  The non-resonant nature of MSAD could provide rapid, high-
throughput analysis of multiple analytes, but it may also complicate data interpretation 
for complex mixtures.  In addition, the charge density dependence of 
MSAD30,31potentially limits its effective dynamic range.  Low concentration samples 
would require long accumulation times and/or large hexapole offset potentials, which 
might adversely affect sensitivity.  Another relevant consideration is that because 
concentration varies across a transient peak (from low to high to low), the extent of 
fragmentation observed across that peak would probably vary as well.  Judicious choice 
of MSAD parameters, including accumulation time and hexapole offset potential, would 
be necessary to optimize the overall figures of merit, and multiplexed scan functions 
might prove beneficial in this regard.  Additional experiments will therefore be required 
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Chapter 4:  Collision-Activated Dissociation and Infrared Multiphoton 
Dissociation of Oligonucleotides in a Quadrupole Ion Trap 
4.1 INTRODUCTION 
Infrared multiphoton dissociation (IRMPD) offers an promising alternative to 
collision-activated dissociation (CAD) in quadrupole ion trap  mass spectrometry.1-11  In 
the quadrupole ion trap (QIT), efficient activation by CAD requires an elevated RF 
trapping voltage, which means that fragments with m/z values less that about one-third of 
the parent ion mass may not be trapped.  In contrast, energy deposition in IRMPD can be 
manipulated independently of the RF level, and as a result low mass fragments not seen 
in CAD spectra can often be observed in IRMPD experiments.  IRMPD is usually 
performed with CO2 lasers, which provide 10.6 µm radiation that is absorbed by a variety 
of organic ions regardless of their m/z value.  Activation is therefore far less specific in 
IRMPD than in CAD, where resonant waveforms are supplied to deposit energy only into 
a narrow population of parent ions but not the ensuing fragment ions.  As a result IRMPD 
can generally provide greater access to secondary dissociation processes and therefore 
supply structural information not readily retrieved by CAD without extensive MSn 
sequences.  Because of these characteristics IRMPD has proved an effective and 
advantageous tool in the analysis of an array of biologically active small molecules 
including macrolide,1 β-lactam,2 tetracycline, 3 and aminoglycoside antibiotics.4 
IRMPD has become an established technique for the analysis of  peptides,12-16 
intact proteins,17-21 and oligonucleotides17,22-28 in FTICR mass spectrometers.  In the 
quadrupole ion trap, however, the utility of IRMPD as a tool in the study of biopolymers 
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is less well characterized.  A few reports describing IRMPD of peptides and proteins in 
the QIT have appeared recently9,10,29,30 but IRMPD of oligonucleotides is limited to a few 
examples.7,11  A systematic comparison of CAD and IRMPD for the analysis of five- to 
forty-residue oligonucleotides has therefore been performed, and the relative utility of the 
two techniques for oligonucleotide sequencing has been evaluated. 
 
4.2 EXPERIMENTAL 
HPLC-purified oligonucleotides were obtained from TriLink Biotechnologies Inc. 
(San Diego, CA) in the ammonium salt form.  Samples for analysis by negative ion 
electrospray contained 10 µM oligonucleotide, 5 mM piperidine, and 5 mM imidazole in 
a 70:30 mixture (v/v) of acetonitrile and water.  Samples for analysis by positive ion 
electrospray contained 20 µM oligonucleotide in a 50:50:1 mixture (v/v) of methanol, 
water, and acetic acid.  Test solutions were infused (0.5 – 1 µl/min) through a custom 
electrospray source consisting of a fused silica sample capillary, stainless steel sheath 
needle, and nitrogen assist gas.   
All experiments were performed with a modified Hitachi M-8000 quadrupole ion 
trap mass spectrometer31 operating in negative ion mode.  To allow IRMPD, a hole was 
cut in the vacuum chamber directly over the ion trap, and a custom flange bearing a 1.5” 
ZnSe window (II-VI Inc.) was bolted over it.  In addition, a 6-mm hole was drilled 
radially through one side of the ring electrode.  The beam from a continuous 50W CO2 
laser (Model 48-5, Synrad Inc., Mukilteo WA) was directed through both the ZnSe 
window and the hole in the ring electrode with a copper mirror (II-VI Inc.).  To trigger 
the laser, TTL pulses generated by the M-8000 software during the ion activation period 
were routed to a laser control module (Synrad Model UC-2000).  For ion isolation a 
temporary DC offset was applied to the trap in lieu of the standard filtered noise field 
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(FNF) waveforms supplied by the M-8000.  DC inputs provided by two external power 
supplies were applied to the endcap electrodes in a dipolar fashion through the RF board 
by means of an in-house switching circuit controlled by software-generated TTL signals.  
This DC/RF approach provided greater ejection efficiency for high m/z ions than the 
RF/FNF strategy employed on the standard M-8000.32  The instrument pressure during 
mass analysis was nominally 5 x 10-5 Torr for all experiments. 
 
4.3 RESULTS AND DISCUSSION 
In this study we have examined the CAD and IRMPD mass spectra for a variety 
of oligonucleotides in order to compare the diagnostic information obtained from each.  
The presence or absence of specific types of fragment ions is noted, as well as the degree 
of sequence coverage afforded by each activation method.  
CAD and IRMPD spectra for the –3 charge state of the 5-mer d(CGTTC) and the 
–4 charge state of the 8-mer d(CGAGCTCG) are shown in Figure 4.1 as representative 
examples illustrating the quality of the data and the types of fragments that can be 
observed.  In both CAD spectra (Fig. 4.1A and C), the dominant ions correspond to loss 
of nucleobases from the intact deoxyribose/phosphate backbone (M-B ions in the 
McLuckey nomenclature).33  These ions relate no sequence information but do 
decompose to informative backbone cleavage products.33  For the 5-mer (Fig. 4.1A), 
thymine is lost in preference to cytosine and guanine.  This behavior is unusual, however, 
and is observed because this particular sequence does not contain adenine.  Results more 
typical of mixed base oligonucleotides are observed for the 8-mer (Fig. 4.1C), where loss 
of  adenine  predominates.34-39   The backbone cleavage products in Figs. 4.1A and C all  
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Figure 4.1: MS/MS data for d(CGTTC) and d(CGAGCTCG).  A) CAD (165 mV/50 
ms) and B) IRMPD (34 W/50 ms) of the 5-mer, -3 charge state.  C) CAD 
(215 mV/50 ms) and D) IRMPD (27 W/50 ms) of the 8-mer, -4 charge state.  
Parent ions are marked with asterisks. 
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belong to the w or a-B series as expected from previous reports.17,33,34 For both of these 
small oligonucleotides, CAD provided complete sequence coverage and a full array of 
complementary fragment ions. 
In the corresponding IRMPD spectra (Fig. 4.1B and D)  the  major backbone 
cleavage products are also w and a-B ions.  In contrast with the CAD spectra, however, 
the M-B ions are greatly reduced in intensity.  This is no doubt a result of non-resonant 
activation in IRMPD and implies that dissociation thresholds for conversion of M-B ions 
to backbone cleavage products are in general lower than those for generation of M-B 
species from of the parent ion.  In addition,  because the low mass cutoff can be 
manipulated independently of ion activation in IRMPD, several low mass ions that could 
not be trapped in CAD experiments are visible in Fig. 4.1B and D.  These include the 
PO3- ion, diagnostic of the phosphate backbone, as well as the deprotonated base anions 
(such as (T-H)-1 in Fig. 4.1B) whose formation is only implied in the CAD spectra by the 
charges on complementary ion pairs (ex. w2-1 and (a3 - T)-1 in Fig. 4.1A).  Both IRMPD 
experiments gave complete sequence coverage in addition to a full array of 
complementary sequence ions on the same time scale used in the CAD experiments. 
In the quadrupole ion trap, the efficiency of photoactivation is somewhat 
compromised by the relatively high operating pressures required for effective trapping 
and resonant ejection.  In several previous studies of IRMPD in the QIT, efficient 
photoactivation has required either unusually low instrument pressure or an unusually 
high temperature. 1,8,9 The spectra in Figs. 4.1B and D, however, were acquired at normal 
instrument pressure and temperature, as were IRMPD spectra for all other oligos in this 
study.  This was possible because of the strong absorbance of 10.6 µm radiation by the 
backbone phosphodiester moieties.7,17  We have recently demonstrated that because of 
the presence of these chromophores, phosphorylated peptides dissociate much more 
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readily by IRMPD in a quadrupole ion trap than the corrresponding non-phosphorylated 
sequences.29  For oligonucleotides the most important cleavage processes occur at the 
phosphate linkages themselves, so in this work clear correlations between absorbance 
cross-section and dissociation thresholds could not be made. 
In IRMPD experiments, energy deposition and dissociation efficiency are 
moderated by adjusting either the laser power or the irradiation time.  To illustrate the 
impact of these parameters on oligonucleotide dissociation, energy-variable IRMPD data 
for the –4 charge state of d(CGAGCTCG) are shown in Figure 4.2.  Increasing either 
exposure time (Fig. 4.2A) or laser power (Fig. 4.2B) increases the proportion of 
backbone cleavage products relative to the parent ion.  Most fragment ions reached a 
relatively constant relative signal intensity, which suggests that secondary dissociation of 
sequence ions is minimal although activation in IRMPD is non-resonant.  This may 
provide indirect evidence of a relationship between absorbance and dissociation, since the 
fragments are smaller than the parent and therefore contain fewer (chromophoric) 
phosphate groups.  It is also potentially significant because destruction of sequence ions 
and loss of sequence information is a disadvantage sometimes associated with IRMPD of 
biomolecules in ICR studies.16 
Dissociation spectra for the –4 and –5 charge states of the 10-mer 
d(ATGCTACGAG) are shown in Figure 4.3.  Results for CAD of the –4 parent ion (Fig. 
4.3A) conform well to literature results.40  In addition, comparison of Fig. 4.3A and C 
illustrates that base loss patterns depend on the charge state of the parent ion.41  For the –
4 charge state the nucleobases were eliminated as neutrals, while for the –5 charge state 
ionic base loss predominated because of greater Coulombic repulsion in the higher charge 
state.41  In the IRMPD spectra (Fig. 4.3B and D), signal intensities for M-B ions were 8- 











Figure 4.2: Energy-resolved IRMPD of d(CGAGCTCG), -4 charge state.  A) Relative 
signal intensity vs. irradiation time, 15.5 W laser power.  B) Relative signal 





















































































Figure 4.3: MS/MS data for d(ATGCTACGAG).  CAD ( 240 mV/50 ms) and B) 
IRMPD (22.5 W/50 ms) of the –4 charge state.  C) CAD (192 mV/50 ms) 
and D) IRMPD (21 W/ 50 ms) of the –5 charge state.  Parent ions are 
marked with asterisks. 
 59
quite low but phosphate and deprotonated base ions were visible, as noted for the 5- and 
complete sequence coverage, and complementary fragments were observed for almost 
every sequence ion.  It is also noteworthy that, in comparing CAD spectra in Figs. 4.1 
and 4.3, some evidence of size discrimination in the activation process is apparent 
because the relative signal intensity for M-B ions is greater for the 10-mer than for the 
smaller oligonucleotides.    
To further explore this possible trend for size discrimination in collisional 
activation, CAD and IRMPD spectra were acquired and compared for longer sequences.  
CAD and IRMPD spectra for the –10 charge state of the 20-mer 
d(GATCCTAGCTAGCTAGGATC) are shown in Figure 4.4.  The size discrimination 
trend observed on going from 8 to 10 residues did seem to perpetuate in the CAD 
experiment (Fig. 4.4A).  From Fig. 4.4B it is clear that extensive dissociation was 
obtained for this 6 kDa analyte by IRMPD.  The charge state of most fragments cannot be 
determined from low-resolution QIT data, so approximately 10-30% of the sequence ion 
assignments are inherently somewhat ambiguous.  However, confidence in many 
assignments was improved in both the CAD and IRMPD spectra because many fragments 
occurred in more than one charge state, and also because complementary w or a-B ions 
were also observed.  Given this, the array of fragments obtained in the CAD and IRMPD 
experiments appears to be quite similar, and the sequence coverage is the same.  The 
yield of sequence ions and the overall sequence coverage obtained by CAD and IRMPD 
for several other charge states of this oligonucleotide are given in Table 4.1, and these 
data show that in general the two activation methods provided similar information. 
Dissociation data for the –14 charge state of the 40-mer oligonucleotide 








Charge State Activation Method w Ions




CAD 17 15 19 
-6 
IRMPD 19 18 19 
CAD 19 16 19 
-7 
IRMPD 19 17 19 
CAD 17 16 19 
-8 
IRMPD 18 16 19 
CAD 17 17 19 
-9 
IRMPD 18 16 19 
CAD 18 17 19 
-10 
IRMPD 16 18 19 
1Sequence ions formed in multiple charge states counted only once. 
 






Figure 4.4: MS/MS data for d(GATCCTAGCTAGCTAGGATC).  A) CAD (240 
mV/50 ms) and B) IRMPD (17.6 W/50 ms) of the –10 charge state.  









Figure 4.5: MS/MS data for d(GACTACAAAGTATGCGACGATGAGGCTAGCTT- 
ACGTAGCCA), -14 charge state.  A) CAD 210 mV/50 ms, B) IRMPD, 
14.8 W/50 ms.  Parent ions are marked with asterisks. 
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Figure 4.5.  (Because of the density of fragment ions, only peaks corresponding to the 
parent ion and M-B fragments are labeled.)  For sequences of this length, only 60-70% of 
sequence ion assignments are unique, but the apparent sequence coverage is nearly the 
same for both CAD and IRMPD.  In both spectra it is apparent that for oligonucleotides 
of this length loss of multiple base moieties can compete with backbone cleavage.  Even 
the uninterpreted data demonstrate that IRMPD can dissociate large species (12kD) as 
effectively as CAD. 
Because free nucleobase ions can be observed so readily by IRMPD, it seemed 
that IRMPD might facilitate the identification of modified residues.  To explore this 
possibility, the 20-mer d(GATCC(N6-MeA)GCTTACGGTACCA) was synthesized and 
analyzed by both CAD and IRMPD.  The resulting spectra obtained from the –8 charge 
state are shown in Figure 4.6.  The mass of the modified base at position 6, N6-
methyladenine, differs from that of guanine by only 2 amu (149.2 amu vs. 151.1 amu).  
The (M-MeAH)-8 and (M-GH)-8 ions for this 20-mer are therefore nearly isobaric, 
differing in mass by only 0.25 mass/charge units.  CAD of the –8 charge state  (Fig.4. 
6A) gave a product at m/z 742.0 that, without prior knowledge of the sequence, could 
reasonably be assigned as an (M-GH)-8 ion (theoretical m/z 741.5).  Similarly, because 
most of the sequence ions in Fig. 4.6A are multiply charged, the majority could be 
assigned incorrectly on the basis of a sequence containing guanine rather than N6-MeA at 
position 6.  Evidence for the modification is subtle in the CAD experiment, and 
additional experiments would likely be required in order to confirm the presence and 
identity of the methylated base. 
In contrast, the spectrum obtained by IRMPD clearly shows a peak at  m/z 148 in 
addition to signals for the anions of the standard bases A, C, G, and T (Fig. 4.6B).  This 
signal provides direct evidence of the modified base along with complete sequence 
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coverage in a single experiment.  The ion at m/z 148 in the IRMPD spectrum was 
isolated and subjected to a second stage of activation, and the resulting MS3 spectrum 
was used to confirm its identity based on a comparison with fragmentation patterns 
generated from authentic adenine and N6-methyladenine (Figure 4.7).  Deprotonated N6-
methyladenine dissociates by loss of H2 or .CH3, pathways identical to those observed for 
m/z 148 in Fig. 4.6B.  The backbone phosphate groups of oligonucleotides are highly 
acidic and deprotonate readily, so oligonucleotides are most commonly analyzed in 
negative ion mode.  Positively charged species can also be generated,42-48 however, so a 
brief comparison of CAD and IRMPD for dissociation of positive charge states was also 
undertaken.  Dissociation data for the +3 and +4 charge states of the 10-mer 
d(GACTACAAGT) are shown in Figure 4.8.  As reported in previous CAD studies,43-46 
the  major sequence ions are still w and a-B species, although they tend to occur in lower 
relative signal intensity in the positive mode.  Consistent with previous reports, the 5’-
terminal base dissociated preferentially to leave prominent GH+ and w9+n ions in all 
spectra.46  The CAD spectrum of the +3 charge state (Fig. 4.8A) does differ somewhat 
from a published spectrum acquired for this sequence in a triple quadrupole.44  A number 
of low mass ions are missing, which is an effect of the low mass cutoff invariably 
associated with CAD in the quadrupole ion trap.  In addition, no cleavage was observed 
3’ to position four, occupied by thymine.  Selectivity against cleavage at T sites relative 
to A, G, and C sites has been noted in several previous studies conducted in quadrupole 
ion traps.37-40  The fact that cleavage was observed at T4 in a triple quadrupole but not in 
the present study is at least in part a reflection of the slightly lower energy regime of the 
QIT.  This notion is also supported by the fact that the M-B ions are far more prominent 
in Figure 8A than in the reference spectrum.   
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Figure 4.6:  MS/MS data for d(GATCCG(N6-MeA)GCTTACGGTACCA).  A) CAD 
(215 mV/50 ms) and B) IRMPD (19.7 W/ 50 ms) of the –8 charge state.  




Figure 4.7: MS/MS data for deprotonated adenine and N6-methyladenine.  A) CAD of 
adenine (M – H)-1, 94 mV/50 ms.  B) CAD of N6-methyladenine (M-H)-1, 
94 mV/50 ms.  C) MS3 of deprotonated N6-methyladenine, m/z 148  133 




Figure 4.8: MS/MS data for d(GACTACAAGT).  A) CAD (245 mV/50 ms) and B) 
IRMPD (18.3 W/50 ms) of the +3 charge state.  C) CAD (180 mV/50 ms) 
and D) IRMPD (16.2 W/50 ms) of the +4 charge state. 
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Comparing the CAD and IRMPD spectra in Fig. 4.8 shows that the effects of the low  
mass cutoff and non-resonant activation noted for IRMPD experiments conducted in 
negative ion mode (trapping of base ions and other low mass species, consumption of M-
B ions) were also evident in positive ion mode, and as in negative mode sequence 
coverage was essentially the same using either activation technique.  The charge state 
dependence of base loss remained consistent as well:  neutral base loss occurred to a 
greater extent for the  lower charge state (Fig. 4.8A vs. C).  However, the parent species 
that tend to lose bases in ionic form carried a lower overall charge in positive than in 
negative ion mode.  The –4 charge state of this oligonucleotide  lost neutral bases upon 
either CAD or IRMPD (data not shown), while the +4 charge state lost protonated bases 
(Fig. 4.8C and D).  This likely occurred because of the high proton affinity of the purine 
and pyrimidine moieties. 
 
4.4 CONCLUSIONS 
IRMPD of deprotonated and protonated oligonucleotides (five to forty residues) 
has been performed in a quadrupole ion trap at normal operating pressure and 
temperature using moderate exposure times and laser powers. In general, IRMPD and 
CAD spectra of any given parent ion contain comparable information, indicating that 
IRMPD is a viable alternative to CAD for oligonucleotide analysis in this instrument 
platform.  However, structurally uninformative M-B ions that dominate CAD spectra are 
usually found much lower signal intensity in IRMPD spectra because of the non-resonant 
nature of photoactivation.  Also, phosphate and nucleobase ions can be observed directly 
in IRMPD experiments because the low mass cutoff can be set to trap small fragment 
ions.  Because of this, analysis of some sequences containing modified bases can be 
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Chapter 5:  Charge State-Dependent Fragmentation of 
Oligonucleotide/Metal Complexes 
5.1 INTRODUCTION 
Metal ions are critical to the in vivo structure and function of DNA and RNA.  
Mono- and divalent cations are thought to induce bending in DNA duplexes,1,2 and are 
also known to stabilize triplex3,4 and quadruplex5,6 structures.  Metal cations are also 
required for the proper folding and function of many forms of RNA, including most 
ribozymes.7,8.  The interactions of DNA with several natural products9 and synthetic 
drugs and drug candidates10,11 are known to be metal-mediated. 
Known as a useful tool for structural characterization and sequencing of nucleic 
acids,12-14 mass spectrometry (MS) has also been employed to characterize a number of 
nucleic acid/metal ion interactions.15  Several previous studies have focused on the 
interactions of the anticancer therapeutic cisplatin or its derivatives with DNA.16-22  
Relatively few studies have addressed binary interactions of nucleic acids and metal 
cations, however.23-27  Most of these studies have focused primarily on complexes with 
the smaller alkali and alkaline earth metals (e.g. Na+, Mg+2), although a few complexes 
with a transition metals25,26 or f-block elements23,25 have also been investigated.   The 
fragmentation behavior of these complexes has been characterized using parent species in 
relatively low charge state (often –2), and the charge state-dependence of the observed 
dissociation pathways has not been evaluated.   
The present study explores the effect of metal complexation on the fragmentation 
patterns of oligodeoxynucleotides (ODN’s) in several different charge states.  A number 
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of different alkali, alkaline earth, and transition metals and several ten-residue sequences 
were employed to form 1:1 complexes, which were subjected to collision-activated 
dissociation (CAD) in a quadrupole ion trap mass spectrometer.  For low charge state 
precursors, distinct changes were observed in the relative intensities of some product ions 
for free vs. metallated ODN’s.  For high charge state precursors,  the metal complexes of 
some sequences exhibited unusual but highly diagnostic fragmentation pathways not 
commonly observed for free ODN’s.  The sequence and metal dependence of these 




HPLC-purified oligonucleotides (ODN’s) were obtained from TriLink 
Biotechnologies (San Diego, CA), Invitrogen (Carlsbad, CA), or IDT (Coralville, IA).  
When necessary ODN’s were converted to the ammonium salt form by either centrifugal 
filtration or ethanol precipitation from ammonium acetate.  Alkali, alkaline earth, and 
transition metal salts (bromides or chlorides) were obtained from Aldrich (St. Louis, MO) 
and were used as received.  Samples containing equimolar amounts of oligonucleotide 
and metal salt at 20-40 µM in 1:3 methanol:water were infused at 3 µL/minute into the 
electrospray source of a ThermoQuest LCQ Duo quadrupole ion trap mass spectrometer 
operating in negative ion mode.  In CAD experiments, activation voltages were applied at 
a level required to reduce the precursor ion to ~10% of its original intensity. 
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5.3 RESULTS AND DISCUSSION 
Oligonucleotides are known to bind metal cations with high affinity.  When 
equimolar amounts of metal salts were added to the ammonium form of a model 
oligonucleotide, the decamer GCGAATTCGC, ODN/metal complexes were readily 
observed for a wide variety of mono- and divalent metal cations, including K+, Rb+, Cs+, 
Ca+2, Sr+2, Ba+2, Mn+2, Co+2, Ni+2, Ag+, Cd+2, Hg+2, and Pb+2.  Several representative ESI 
spectra are shown in Figure 5.1.  For all metals investigated, the 1:1 ODN:metal 
stoichiometry was observed in multiple charge states (typically –2 to –6), although higher 
stoichiometries were also observed for the late transition metals (Ni+2, as shown in Fig. 
5.1D; also Co+2 and Ag+).  The exact mode by which metal cations bind DNA remains 
unclear, but some evidence indicates that transition metals can bind DNA nucleobases, 
while alkali and alkaline earth metals prefer the backbone phosphodiester groups.28  The 
relative intensities for 1:1 ODN:metal complexes in Fig. 5.1 could be interpreted as 
support for this notion:  transition metals may produce higher stoichiometries and greater 
signal intensities because they can readily bind the bases and therefore need not compete 
with the ammonium counterions for phosphodiester binding sites.  Alkali and alkaline 
earth cations, on the other hand, may compete less effectively for phosphodiester sites 
occupied by ammonium counterions, which are present in excess relative to the added 
metal salts.   
To evaluate the effect of different metals on oligonucleotide fragmentation, CAD 
spectra were first acquired for the [ODN – nH]-n ions (n = -2 to -6) formed with 
GCGAATTCGC.   CAD experiments were then performed for the analogous [ODN – nH 




Figure5.1: ESI mass spectra for GCGAATTCGC in the presence of various metal salts.  
A) KCl, B) CaCl2, C) BaCl2, and D) NiBr2.  Complexes at the 1:1 
stoichiometry are marked with open triangles ( ), and complexes at the 1:2 

















series of metal cations.  Compared to the deprotonated precursors, some of the metal 
adducts demonstrated distinctly different fragmentation behavior in both low and high 
charge states.  The metals most likely to produce unusual fragmentation were identified, 
and a representative metal (Ba+2) was chosen for additional experiments with different 
oligonucleotides to investigate the sequence dependence of these dissociation processes. 
 
5.3.1 Fragmentation of Low Charge State Precursors 
Representative dissociation data for the –2 charge states of GCGAATTCGC and 
its 1:1 complex with Ba+2 are shown in Figure 5.2. For the deprotonated ODN, the most 
abundant ions in the spectrum represent loss of neutral nucleobases (detailed in Fig. 5.2A, 
inset), resulting in M-B ions that retain the intact phosphate backbone.  Secondary 
dissociation of these ions produced an array of backbone cleavage products (“sequence 
ions“) labeled wn and an-B according to the McLuckey nomenclature.29  The general 
mechanism shown in Scheme 5.1 has been proposed to explain the formation of these 
kinds of fragments.30,31  The assortment of sequence ions visible in Fig. 5.2A indicates 
that cleavage has occurred at nearly every interresidue junction along the phosphate 
backbone, as indicated by the series of slash marks overlaid on the sequence shown in 
Fig. 5.2A.  As originally described by Favre et al32, the charges on these sequence ions 
convey the preferred locations of the negative charges.  For example, the w ion series in 
Fig. 5.2A consisted of w2-1, w5-1, w6-1, w8-2, and w9-2 species.  The fact that w5-2 and w6-2 
species were not observed suggests that in the activated parent species, the total charge 
was not distributed statistically along the phosphate backbone, but was instead confined 
near the 5’- and 3’-termini.  Analysis of the a-B ion series in Fig. 5.2A supports the same 
conclusion, which is also consistent with results for different sequences in previous 





Figure 5.2: CAD spectra for the –2 charge state of GCGAATTCGC and its 1:1 complex 
with Ba+2.  A) ODN alone (0.75V/30 ms) and B) Ba+2 complex (0.88V/30 
ms).  Parent ions are marked *, and fragments identified with an asterisk and 
a standard sequence ion identifier (e.g. *w8-2) correspond to sequence ions 
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The CAD spectrum acquired for the 1:1 barium complex of the same decamer is 
shown in Fig. 5.2B.  The m/z values for many of the resulting fragments indicated that 
the ODN-Ba+2 interaction survived collisional activation. These fragments include the M-
B species (Fig. 5.2B inset) as well as a number of w and a-B ions, which are marked with 
asterisks to distinguish them from non-metallated w and a-B species.  The combined 
array of both metallated and non-metallated sequence ions indicates that the Ba+2 
complex produced the same overall sequence coverage as the free ODN (Fig. 5.2A), 
which is consistent with previous dissociation studies conducted with ODN/metal 
complexes.23,24  In addition, the distribution of charge among the sequence ions suggests 
that one negative charge was localized near each end of the sequence, as described above 
for the free ODN.  It is important to note, however, that metal cations provide partial 
charge balance for species of the general formula [ODN – nH + M+m]-(n-m), and that the 
fragment ion charges can only be used to determine the position of the “excess” charges.  
Additional deprotonation sites counterbalanced by the metal cation must also exist, and 
these cannot be determined solely from the charge states of the sequence ions.  The 
preferred localization of the metal cation itself can be estimated, however, by examining 
which sequence ions retain the metal.24  In Fig. 5.2B, for example, the smallest w species 
retaining Ba+2 was the *w5-1 ion and the smallest a-B species retaining Ba+2 was the *(a8-
C)-2 ion.  The approximate location of the Ba+2 ion should correspond to the portion of 
the original sequence common to both these fragments (i.e. the pTpTp motif), as 
illustrated in Scheme 5.2.  The fact that the metal resides near the middle of the sequence 
is consistent with results reported for series of sodium-adducted ODN’s.24 
In several respects (sequence coverage, the location of the negative charges, and 
the location of the metal cation), the data in Figure 5.2 correlate well with previous 

































































































in one respect, as illustrated by the insets in Fig. 5.2A and B, which are expansions of the 
base loss region of the CAD spectra.   For the deprotonated ODN, the most intense M-B 
ion represented loss of neutral guanine, which is typical of mixed-base oligonucleotide 
sequences in low charge states.33  For the Ba+2 adduct, however, loss of cytosine was the 
predominant process as indicated by the enhanced intensity of the M-CH ion.  As 
indicated in Scheme 5.1, M-B species are intermediates that dissociate further to yield 
sequence ions.  While loss of cytosine in and of itself is not atypical, loss of  either 
adenine or guanine usually predominates, although the reasons for this are not well 
understood.34  The enhanced loss of cytosine seen in Fig. 5.2A was found to depend on 
the identity of the metal complexed to the ODN, as illustrated in Fig. 5.3, which shows 
the base loss regions of the CAD mass spectra for ODN complexes containing different 
metal ions.  Collisional activation of alkali or transition metal complexes produced 
different base loss patterns than the free ODN (Fig. 5.3A), as indicated by representative 
spectra for K+ and Ni+2 (Fig. 5.3C and E).  However, loss of cytosine was most strongly 
favored by complexation with the alkaline earth metals.  The relative intensity of the M-
CH ions were greatest for 1:1 adducts with Ba+2, Sr+2 and Ca+2; CAD spectra for Ba+2 and 
Ca+2 are shown in Fig. 5.3B and D, respectively.   
Previous studies have shown that loss of cytosine is enhanced for fully metallated 
oligonucleotides, i.e. those where all phosphodiester counterions are metals.27  To explain 
this enhancement the mechanism illustrated in Scheme 5.3 was proposed and supported 
with CAD results for deuterated precursor ions.27  In this route, protons are transferred to 
the nucleobase from the 2’ position of the deoxyribose ring, rather than the 5’-phosphate 
group as in the standard mechanism (Scheme 5.1).  Subsequent base loss and cleavage at 
the 3’ phosphate then generates the usual w and a-B sequence ions.  Under these 
conditions, loss of cytosine and thymine typically predominates over loss of adenine and   
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Figure 5.3:  Base loss regions of CAD spectra for GCGAATTCGC and several 1:1 metal 
adducts in the –2 charge state.  A) ODN alone (0.75V/30 ms), B) 1:1 adduct 
with Ba+2 (0.85V/30 ms), C) 1:1 adduct with K+ (0.95V/30 ms), D) 1:1 
adduct with Ca+2 (0.9V/30 ms), and E) 1:1 adduct with Ni+2 (0.78V/30 ms).  
Parent ions are marked *.  
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guanine because the pyrimidines possess tautomeric forms that place electron-rich 
moieties in the proximity of the ribose ring.  The mechanism depicted in Scheme 5.3 does 
not fully explain the dissociation patterns observed in Figs. 5.3B-E, however.  This route 
predicts facile loss of thymine as well as cytosine, and essentially no loss of thymine was 
observed for any of the metal complexes investigated in our study.  Furthermore, this 
mechanism was proposed to be operative at much higher metal:ODN stoichiometries, i.e. 
when all backbone phosphate protons are replaced with metal counterions.  The parent 
ions in Figs. 5.3B and D contain only one metal cation, and therefore retain several acidic 
protons available for transfer to a nucleobase.   
In an attempt to gain more insight into these unusual base losses, additional 
experiments were undertaken to determine what if any sequence dependence might exist.  
Fragmentation patterns were acquired for the –2 charge state of several other 10-residue 
oligonucleotides and with their 1:1 complexes with Ba+2.  To facilitate comparisons with 
the data in Fig. 5.2, these additional sequences all shared the base composition A2C3G3T2.  
CAD results obtained for the ODN’s GAATTCGCGC, GCGCGAATTC, 
CGCTTAAGCG, and AAGCGCGCTT, were quite similar to those shown in Fig. 5.2: 
loss of guanine dominated for the [M – 2H]-2 precursors, and loss of cytosine dominated 
for the [M – 4H + Ba+2]-2 precursors (data not shown).   This uniform behavior suggests 
that the position of the cytosine residues along the sequence played little role in the 
observed fragmentation behavior.  However, Ba+2 adduction did not significantly affect 
the base loss pattern for the sequence ACGTCTGCAG, as shown in Figure 5.4.  In this 
case, the loss of guanine dominated the CAD spectra of both the free ODN (Fig. 5.4A) 
and the 1:1 barium adduct (Fig. 5.4B), and the loss of cytosine was comparable for both 
parent ions.  It is not entirely clear why the CAD patterns for ACGTCTGCAG differ 





Figure 5.4: CAD spectra for the –2 charge state of ACGTCTGCAG and its 1:1 complex 
with Ba+2.  A) ODN alone (0.75V/30 ms) and B) Ba+2 complex (0.78V/30 
ms).  Parent ions are marked *, and fragments identified with an asterisk and 
a standard sequence ion identifier (e.g. *w8-2) correspond to sequence ions 
that retain the metal ion. 
 
 






























which the loss of cytosine was enhanced upon barium complexation, the residue at the 3’-
terminus was the Watson-Crick complement of the residue at the 5’-terminus.  This is not 
true of ACGTCTGCAG, the only sequence that did not exhibit a change in base loss 
pattern.  This points to intramolecular base pairing, and therefore gas-phase 
conformation, as a significant factor:  metal complexation may change the gas-phase 
conformation (and/or conformational dynamics) for some sequences, providing access to 
alternative mechanisms for proton transfer and subsequent base loss.  Relatively little is 
known about the gas-phase conformation of oligonucleotides, although some results from 
preliminary ion mobility experiments have recently appeared.35-39 
Fragmentation data for GCGAATTCGC and its 1:1 Ba+2 complex in the –3 
charge state (not shown) produced (M-BH)-3 species with intensity patterns similar to 
those visible in Fig. 5.2, which indicates that the factors controlling base loss processes 
for ODN’s vs. their barium complexes were also operative at a higher charge state.  CAD 
spectra acquired for the –4 charge states of GCGAATTCGC and its 1:1 Ba+2 complex are 
given in Figure 5.5A and B, respectively, and the base loss patterns in Figs. 5.5A and B 
are again different.  For this charge state, however, the parent ions lose adenine as the 
major process, which is entirely consistent with previous literature reports for collisional 
activation of deprotonated oligonucleotides in intermediate charge states.33,40,41 As was 
observed for the –2 charge state, the Ba+2 complex in the –4 charge state produced the 
same overall sequence coverage as the deprotonated ODN alone, and analysis of the 
metallated sequence ions indicated that the metal cation again localized preferentially at 
the pTpTp motif of the parent ion.  Comparison of Figs. 5.2B and 5.5B illustrates that the 
M-B species became less dominant for the metal complex as charge state increased.  This 
may mean that the difference between the threshold energy levels required for base loss 






Figure 5.5: CAD spectra for the –4 charge state of GCGAATTCGC and its 1:1 complex 
with Ba+2.  A) ODN alone (0.75V/30 ms) and B) Ba+2 complex (0.80V/30 
ms) .  Parent ions are marked *, and fragments identified with an asterisk 
and a standard sequence ion identifier (e.g. *w6
-3) correspond to sequence 
ions that retain the metal ion. 
 
 































charge states.  A similar difference in threshold energies may also explain the fact that 
sequence ions produced by the ODN:Ba+2 complex in Fig. 5.5B are more intense than the 
sequence ions visible in Fig. 5.5A.  In addition, the intensity of sequence ions at higher 
m/z values than the parent ion was often greater in the spectrum of the Ba+2 complex than 
in the spectrum for the deprotonated ODN alone (ex. w6-2 vs. *w6-2 in Figs. 5.5A and B).   
 
5.3.2 Fragmentation of High Charge State Precursors 
Fragmentation data for the –5 charge state of GCGAATTCGC and its 1:1 Ba+2 
adduct are given in Figure 5.6A and B.  The spectrum in Fig. 5.6B is remarkable in 
several respects:  the M-B ions, which normally dominate CAD spectra for 
oligonucleotides acquired in quadrupole ion trap instruments, occur in unusually low 
signal intensity.  Furthermore, the dominant product ions, at m/z 965.5 and 408.7, are 
consistent with the assignments *a6-2 and w4-3, respectively.  The CAD spectra of 
oligonucleotides rarely contain an-n ions as major species.  The presence of the *a6-2 ion 
along with the complementary w4-3 ion with similar signal intensity indicates that direct, 
site-specific backbone cleavage (no preceding base loss) has taken place.   To confirm the 
assignment of m/z 965.5, an MS3 experiment was performed, and the resulting spectrum 
(Figure 5.7) supports assignment of m/z 965.5 as the *a6-2 ion. Fragments assigned as *a5-
1 and *a4-1 ions were observed along with the complementary [thymine monophosphate – 
H2O]-1 and [pAT-H2O]-1 ions, indicating that the *a6-2 ion also dissociated by direct 
backbone cleavage.   Some products of cleavage preceded by base loss (likely by the 
mechanism shown in Scheme 5.2) are also visible (e.g. *[a6-T]-2) in Fig. 5.7.   
The formation of the unusual *a6-2 species was found to be strongly metal 
dependent.  The relative intensity of the *a6-2/w4-3 complementary pair decreased in the 
order Ba+2, Sr+2 > Ca+2, Pb+2, > K+, Rb+, Cs+, Mn+2, Co+2, Ni+2, Cd+2, Hg+2. 
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Figure 5.6:   CAD spectra for the –5 charge state of GCGAATTCGC and its 1:1 
complexes with several metal cations.  A) ODN alone (0.75V/30 ms), B) 
Ba+2 complex (0.88V/30 ms), C) Ca+2 complex (0.88V/30 ms) , and D) K+ 
complex (0.90V/30 ms) . Parent ions are marked *, and fragments identified 
with an asterisk and a standard sequence ion identifier (e.g. *w5-2) 
correspond to sequence ions that retain the metal ion. 
 
 











































Figure 5.7:   MS3, (GCGAATTCGC + Ba+2- 7H)-5  m/z 965.5  ? (0.88mV/30 ms; 
0.95V/30 ms).  The parent ion is marked * and fragments identified with an 
asterisk and a standard sequence ion identifier (e.g. *a5
-1) correspond to 





















Representative spectra acquired for complexes with Ca+2 and K+ are shown in Figure 
5.6C and D, respectively.  Comparing the CAD spectra for the complexes with  Ba+2 
(ionic radius 149 pm) and Ca+2 (114 pm)  indicates that larger metal ions promote the 
formation of the *a6-2  product ion more effectively than smaller ions carrying the same 
ionic charge (Fig. 5.6B vs. C).  Likewise, comparing data for Ba+2 and K+, which have 
similar ionic radii (149 vs. 152 pm) but different net charges, indicates that greater ionic 
charge also facilitates formation of the *a6-2 product ion (Fig. 5.6B vs. D).  Results for 
other metal ions suggests that other factors are probably also operative: for example, the 
complex with Pb+2 gave the *a6-2 ion in somewhat lower intensity than the complex with 
Sr+2, which could be due to a difference in electronegativity (0.95 for Pb+2 vs. 1.87 for 
Sr+2), orbital configuration (two vs. zero valence electrons), or both.   
The formation of the *a6-2 species was also found to be strongly sequence 
dependent.  Data for the relative intensity of the *a6-2 fragment for different ten-residue 
sequences is compiled in Table 5.1 and presented in a semi-quantitative fashion.  The 
barium complexes of two unrelated sequences (ATGCTACGAG and GACTACAAGT) 
did not produce *a6-2 ions, showing that the direct backbone cleavage process is not a 
general phenomenon.  The first five entries in Table 5.1, taken as a collective, indicate 
that the middle of the sequence greatly influences the direct backbone cleavage process.  
In a particularly striking result, replacing the central “AATT” motif in the original 
sequence with the alternating sequence “ATAT” completely prevented the formation of 
*a6-2 ion.  The sequence GCAAATTTGC, which incorporates additional A and T 
residues, produced a strong *a6-2 ion, but the alternating version of this sequence 
(GCATATATGC) also gave the *a6-2 product with significant (albeit somewhat lower) 
intensity.  The 10mer GCGCATGCGC, which contains fewer A/T residues, also 


















Table 5.1:   Sequence dependence of *a ion formation upon CAD of 1:1 Ba+2 complexes 














Relative Intensity, *a Sequence
 94
indicate that the AT motif at positions 5 and 6  is critical, and that sequential A and T 
residues around these positions is supportive.  Point substitutions at these sites, as in the 
sequences GCGAGTTCGC and GCGAACTCGC, show that the thymine residue at 
position 6 is more critical to the formation of the *a6-2 ion than the adenine at position 5.  
Three sequence variants (GCGCGAATTC, GAATTCGCGC, and CGCTTAAGCG) all 
produced metallated an-m ions in only low intensity, which indicates that both the position 
and directionality of the AT motif are significant.  This may mean that the proximity of 
the AT motif to the metal center may be critical, because for all of the decamers listed in 
Table 5.1, the distribution of the metal cation among the observed fragment ions indicates 
that the Ba+2 ions bound near the middle of the sequence (i.e. near positions 5 and 6).   
Direct cleavage of the phosphate backbone of deprotonated oligonucleotides to 
yield an-m ions has been observed in certain circumstances.  Favre et al observed a 
number of an-m ions upon collisional activation of deprotonated polythymine, a result that 
was ascribed to the low proton affinity of thymine.32  ODN’s with strictly uncharged 
backbone sites (either methylphosphonates42 or TMS-derivatized phosphates43) have also 
been shown to undergo direct backbone cleavage at a site adjacent to the neutral linkage.  
One mechanism proposed to explain such cases42, shown in Scheme 5.4, involves proton 
transfer from the 4’ position of ribose to the neutral phosphodiester linkage followed by 
cleavage of the 3’ ribose-linker bond.  Presumably, the mechanism in Scheme 5.4 could 
also operate in cases where a standard but neutral phosphodiester linkage is present, i.e. 
when the R group in Scheme 5.4 = OH.  Neutral backbone sites must be present in the 
ODN/Ba+2 complexes under investigation:  the decamers contain a total of nine acidic 
(i.e. phosphodiester) hydrogens, so [ODN – nH + Ba+2](n-2) complexes carrying a net 
charge of –5 would retain two acidic protons on the phosphate backbone.  These  






Scheme 4:   Proposed mechanism for direct cleavage of the phosphate backbone to 
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metal coordination may sequester acidic protons at certain positions along the phosphate 
backbone. 
This concept is illustrated in Scheme 5.5A for the [d(GCGAATTCGC) – 7H + 
Ba+2]-5 ion.  In accordance with CAD data for this complex (Fig. 5.6B), the Ba+2 cation is 
shown to be bound somewhere along the internal pTpTp subsequence.  The negative 
charges are assumed to reside only on phosphodiester groups and are assigned to 
phosphodiesters 1-4 and 7-9 (relative to the 5’-terminus).  This leaves neutral sites at 
phosphodiesters 5 and 6, which could lead to direct backbone cleavage by the mechanism 
in Scheme 5.4 to produce the *a6-2 ion along with its complement, the w4-3 ion.  The 
presence of a neutral phosphodiester at position 5 in the *a6-2 ion could then yield an a5 
product on MS3, which was indeed observed (Fig. 5.7).  Experimentally, however, the 
metallated a5 species seen in  Fig. 5.7 carries a net charge of –1, and the complementary 
(TMP – H2O) ion (which contains the critical neutral phosphodiester) also carried a net 
charge of –1.  This is difficult to reconcile by the route shown in Scheme 5.5A, where 
phosphodiester 5 is assigned as a neutral site, unless extensive proton transfer from other 
sites takes place.   
An alternative route is presented in Scheme 5.5B.  Here the possibility of 
deprotonation at both phosphodiester and nucleobase moieties is considered.  (In general 
the nucleobases are far less acidic than the phosphodiester groups, but both guanosine 
and thymidine can be deprotonated in solution at high pH (pKa = 9.2 and 9.8, 
respectively).44  In the gas phase, internal Coulombic repulsion in highly charged 
oligonucleotide anions could increase the likelihood of deprotonation of guanine and/or 
thymine residues.)  If it is assumed that the critical thymine residue at position 6 is 
deprotonated and a specific interaction between this residue and the metal cation is 























Scheme 5.5: Possible route to *a ions from the -5 charge state of (GCGAATTCGC + 
Ba+2 - 7H)-5.  A) Negative charges assigned exclusively to 
phosphodiester groups and B) negative charges allowed on both 
phosphodiester groups and nucleobase moieties.    
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then a neutral site can be assigned to phosphodiester 4, as shown.  Like the scenario in 
Scheme 5.5A, this permits direct cleavage of the parent species to produce an *a6-2 
product ion according to the route in Scheme 5.4.  However, Scheme 5.5B better 
reconciles the MS3 data obtained for the *a6-2 ion in several respects.  First, charge 
balance in the conversion of *a6-2 to *a5-1 + (TMP – H2O)-1 by Scheme 5.4 is more 
readily explained if phosphodiester 4 is neutral.  Second, the presence of a formally 
charged thymine residue allows the possibility of anionic base loss, which could explain 
the large difference in relative intensities of the *a5-1 and (TMP – H2O)-1 ions in Fig. 5.7.  
(As complementary species, these ions would be expected to form with similar relative 
intensities.  A (T-H)-1 ion, if formed, would be seen at m/z 110, which is below the low 
mass cutoff of the spectrum in Fig. 5.7).  Third, the presence of the *a4-1 product ion in 
Fig. 5.7 could form by the route in Scheme 5.4 if phosphodiester 4 is neutral.  A 
reasonable route to this product ion is less readily conceived from Scheme 5.5A. 
In sum, Scheme 5.5B presents a picture for the formation of metallated an-m 
fragments from  [d(GCGAATTCGC) – 7H + Ba+2]-5 ion that is generally consistent with 
what is known of the factors influencing the direct cleavage process.  The low proton 
count agrees with the observed charge state dependence.  The notion that a 
(deprotonated) thymine residue at position 6 might be involved is generally consistent 
with the sequence dependence indicated in Table 5.1.  It should be acknowledged, 
however, that Scheme 5.5 rationalizes only the major fragmentation pathways observed 
for the [d(GCGAATTCGC) – 7H + Ba+2]-5 ion (and its *a6-1 product ion).  Other, less 
significant pathways are also observed in both Fig. 5.3B and Fig. 5.7, implying that 
multiple populations with different deprotonation and/or metal complexation sites may 
well exist and interchange.  
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The possibility of multiple populations is also highlighted by CAD data obtained 
for 1:1 metal complexes in the –6 charge state.  The Ba+2 complexes of only a few of the 
decamers listed in Table 5.1 (GCGAATTCGC, GCAAATTTGC and GCGAGTTCGC) 
produced detectable *an-m ions.  A representative spectrum for the barium complex of 
GCGAATTCGC is shown in Figure 5.8, and illustrates that for this precursor charge state 
the metallated an-m species formed in lower relative intensity but greater variety.  If 
negative charges occur exclusively at phosphodiester moieties, then ions of the formula 
[ODN – nH + Ba+2]-6 would retain only one neutral backbone site.  If this neutral site 
drives direct backbone cleavage, as Scheme 5.4 hypothesizes, the distribution of different 
*an-m ions in Fig. 5.8 indicates that this “last” neutral site delocalizes over several 
positions along the backbone.   
 
5.4 CONCLUSIONS 
For low to intermediate charge states, metal adduction altered the relative 
intensity of M-B species produced for several ten-residue ODN’s, promoting loss of 
cytosine rather than loss of guanine.  The relative intensities of sequence ions were 
largely unaffected.  This behavior was most prevalent for alkaline earth cations Ca+2, 
Sr+2, and Ba+2, and for isomeric ODN’s with complementary residues at the 5’- and 3’-
termini.  This suggests that metal complexation may change the gas-phase conformation 
for some sequences, possibly providing access to alternative mechanisms for proton 
transfer to and subsequent loss of the nucleobase moieties. 
In higher charge states, CAD of some metal adducts of GCGAATTCGC produced 
intense fragment ions corresponding to metallated a6-2 ions.  These species result from 
direct cleavage of the phosphate backbone (with no prior loss of nucleobase) and are not 







Figure 5.8: CAD spectra for the 1:1 adduct of GCGAATTCGC and Ba+2 in the -6 
charge state (0.90V/30 ms).  The parent ion is marked *, and fragments 
identified with an asterisk and a standard sequence ion identifier (e.g. *w5-3) 
correspond to sequence ions that retain the metal ion. 
 


















adducted ODN’s is highly dependent on the identity of the metal, being most favored by 
large divalent cations with empty valence shells such as Ba+2 and Sr+2.  This behavior 
was also strongly dependent on sequence, being most prevalent for sequences with a 
thymine residue at position 6.  Literature precedent exists for the formation of an-m ions 
from sequences in which covalent modification generates one or more neutral sites along 
the phosphate backbone.  ODN/metal adducts in high charge states possess only a few 
acidic protons, and the juxtaposition of these neutral phosphate groups near thymine 
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Chapter 6:  Influence of Initial Charge State on Fragmentation Patterns 
for Non-Covalent Drug/DNA Duplex Interactions 
6.1 INTRODUCTION 
A  hallmark of electrospray ionization mass spectrometry (ESI-MS) is its ability 
to ionize non-covalent complexes without disrupting fragile intermolecular interactions.1-
5  Because of this property, ESI-MS has been used to investigate a number of non-
covalent interactions known or thought to be important in the function of DNA and RNA, 
including DNA duplexes,6-11 triplexes,12 and quadruplexes,12,13, as well as drug/DNA7,8,14-
21 or drug/RNA complexes.22-26 In such studies ESI-MS has been used to assess binding 
stoichiometry, metal ion requirements for binding, and relative binding affinity, and has 
also been used to estimate solution binding constants.   
A second important characteristic of ESI is that it tends to produce multiply 
charged ions for analytes possessing multiple protonation or deprotonation sites.  
Fragmentation patterns of proteins27-30 and single-stranded oligonucleotides31,32 are 
known to vary with the charge state of the parent ion.  Previous studies10,14 have shown 
that the collisional activation energy required to dissociate DNA duplexes varies 
inversely with charge state.  In terms of fragmentation pathways, it has been shown that 
under fast heating conditions (e.g. in quadrupole/TOF instrumentation), non-covalent 
strand separation predominates for all but the lowest charge states, which can also 
undergo covalent bond cleavage.11  For a given precursor, covalent cleavage pathways 
become more significant in spectra acquired on quadrupole ion trap (QIT) 
instrumentation, which reflect slow heating conditions.11  Both covalent and non-covalent 
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dissociation have been reported for various DNA duplex/drug complexes in the QIT, and 
general correlations have been drawn between the predominant fragmentation pathway 
and the mode of drug binding to the duplex.8  No information has been reported on how 
charge state affects the fragmentation patterns of DNA duplex/drug complexes, however.  
We have therefore investigated this issue using collision-activated dissociation (CAD) in 
a quadrupole ion trap mass spectrometer (QIT-MS).  Several self-complementary 10-
residue oligonucleotides were employed, in addition to a number of DNA-interactive 
drugs, including the intercalators daunomycin and nogalamycin, and the minor groove 
binding agents distamycin, netropsin, 4,6-diamidino-2-phenylindole, and Hoechst 33342, 
(structures shown in Figure 6.1).  In general, the dissociation pathways exhibited by both 
the duplexes and the drug/duplex complexes were found to be markedly sensitive to 
initial charge state.  Results for the drug/duplex complexes were interpreted in terms of 
the known binding mode of the drug and the observed dependence of fragmentation on 
activation time.  Data for the quinolone antibiotic norfloxacin, which interacts with DNA 
in a fashion that is poorly understood, was also acquired and evaluated.     
 
6.2 EXPERIMENTAL 
All DNA-interactive drugs were purchased from Sigma (St. Louis, MO) and used 
as received.  The self-complementary oligodeoxynucleotides (ODNs) 5’-
GCGCATGCGC-3’, 5’-GCGAATTCGC-3’, and 5’-GCAAATTTGC-3’ were purchased 
from TriLink Biotechnologies (San Diego, CA) as HPLC-purified ammonium salts.  To 
form DNA duplexes, stock solutions containing ODN (1 mM) and ammonium acetate (1 
M) were annealed at 90°C for ten minutes and slowly cooled to room temperature over 






















Figure 6.1. Structures of DNA-interactive drugs used in this study. Compound 





















































































divalent metal salt (where applicable) were prepared in 25% methanol containing 50 mM 
ammonium acetate at a nominal pH of 6.5.  The solutions were allowed to equilibrate at 
room temperature prior to analysis.  Electrospray ionization mass spectra were collected 
on a ThermoQuest LCQ Duo ion trap mass spectrometer equipped with an electrospray 
ionization source operating in the negative ionization mode.  The analyte solution was 
introduced into the instrument by direct infusion at a flow rate of 3 µL/min.  A heated 
capillary temperature of 90°C was used to ensure adequate desolvation while minimizing 
in-source dissociation of the non-covalent complexes.  In CAD experiments, activation 
voltages were applied at a level required to reduce the selected parent complex to ~10% 
of its original intensity.  The instrument’s default activation time of 30 ms was used 
except where noted.  Since activation time and activation voltage vary inversely, greater 
activation voltages were required when activation times were decreased, and vice versa. 
 
6.3 RESULTS AND DISCUSSION 
Our objective was to unravel some of the parameters that influence the 
dissociation pathways of DNA/drug complexes in order to determine the extent to which 
binding modes are reflected in the CAD mass spectra.  First, the CAD patterns of the 
duplexes alone were evaluated as a function of the rate of energy deposition (a function 
of the activation time and applied collisional activation voltage) in order to allow 
benchmark comparisons to the dissociation behavior of the duplex/drug complexes.  Then 
the fragmentation patterns of a variety of duplex/drug complexes were studied to allow 
systematic investigation of the impact of the drug, the oligonucleotide sequence, the 
collisional activation time, and the stoichiometry of the duplex/drug complexes on the 
observed dissociation pathways. 
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6.3.1 Dissociation of DNA Duplexes 
Gas-phase DNA duplexes are known to dissociate in the gas phase by one of two 
pathways:  non-covalent cleavage (i.e. strand separation or “unzipping”) to yield two 
single-stranded species, or covalent cleavage to yield either fragments of single strands 
(Type I products) or partial duplexes from which either base loss or backbone 
fragmentation of one strand has occurred (Type II products).11  Previous studies have 
shown that the tendency for covalent cleavage increases with the number of interstrand 
hydrogen bonds, i.e. for longer vs. shorter duplexes and GC- vs. AT-rich sequences.6,8,9,11  
Low energy collisional activation also promotes covalent cleavage, so instrument 
platforms that provide slow heating conditions are more likely to yield covalent vs. non-
covalent dissociation products.11 
To study the effect of charge state on duplex fragmentation, both [ds]-5 and [ds]-4 
species were generated by electrospray ionization of d(GCGAATTCGC)2 (Fig. 6.2A).   
(Although the ion at m/z 1513 cannot be unambiguously assigned as [ds]-4 or [ss]-2 based 
solely on its mass-to-charge ratio, examination of the spacing of the associated sodium 
adduct peaks suggests that [ds]-4 is the major species.)  Collisional activation of the [ds]-5 
ion using a CAD time of 30 ms produced only non-covalent strand separation (Fig. 6.2B), 
a result that was found to be insensitive to activation time (data not shown).  In contrast, 
CAD of the [ds]-4 ion using a 30 ms activation period (Fig. 6.2D) gave several Type II 
products (e.g. [ds – GH]-4, [ds – a4]-3, etc.), indicating that covalent cleavage of the 
duplex was a major process under these conditions.  This result was found to be strongly 
dependent on the activation time:  a shorter activation period and correspondingly greater 
collisional activation voltage (3 ms,  1.3 V, Fig. 6.2C) gave products of single strand 
dissociation   (Type I products),  while  a  longer  activation  time  and  lower  activation  
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Figure 6.2: ESI and CAD product ion spectra for d(GCGAATTCGC)2:   (A)  full scan 
mass spectrum,  (B)  CAD of  [ds]-5,  0.5V/30 ms  activation,  (C) CAD of  
[ds]-4, 1.3V/3 ms activation (D) CAD of [ds]-4, 0.70V/30 ms activation, and 




































voltage (300 ms, 0.50 V, Fig. 6.2E) gave mostly Type II fragments of duplex 
dissociation.  The dominance of the [ds – GH]-4 ion at m/z 1475 in Fig. 6.2E confirms 
that the parent ion population at m/z 1513 consisted almost exclusively of the [ds]-4 
species, with little contribution from [ss]-2.  The fragments in Fig. 6.2C must therefore 
result from a two-step process involving non-covalent strand separation ([ds]-4  2 [ss]-2) 
followed by covalent cleavage of the resulting single strands.  This is consistent with the 
activation time dependence that was reported by Gabelica and De Pauw11 and interpreted 
as an effect of entropy:  non-covalent dissociation is favored entropically, whereas base 
loss is a multi-step rearrangement that is entropically disfavored.  The fact that the non-
covalent pathway was less prevalent for the lower charge state at moderate activation 
times (Fig. 6.2B vs. D) likely reflects the lower degree of internal Coulombic repulsion in 
the [ds]-4 parent.   
Similar to the CAD results obtained for d(GCGAATTCGC)2, CAD spectra for the 
[ds]-5 ions for the duplexes d(GCGCATGCGC)2 and d(GCAAATTTGC)2 exhibited 
strand separation in a time- and activation voltage-independent fashion (not shown).  
Results for the [ds]-4 charge states demonstrated some sequence dependence, however. 
(Note that [ds]-4 species were so identified in each case because of the spacing of the 
associated sodium adduct peaks.)  Type II fragments were insignificant for all three 
duplexes when an activation time of 3 ms was employed, and Type I products of single 
strand cleavage (e.g. [ss-GH]-2) were predominant.  As the activation time was increased 
to 30 ms, Type II products became dominant for d(GCGCATGCGC)2, and products of 
single-strand fragmentation were far less intense than for d(GCGAATTCGC)2 (in Fig. 
6.2D).  CAD of d(GCAAATTTGC)2 at 30 ms produced Type II fragments in low 
proportion, and products deriving from cleavage of single-stranded species were 
prevalent.  These results indicate that at a fixed, moderate activation time and voltage, the 
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relative intensity of Type II fragments decreased as the GC content of the sequence 
decreased, in agreement with previously reported trends.11 
 
6.3.2 Dissociation of Drug/Duplex Complexes 
Small molecules that interact with DNA typically bind Watson-Crick duplexes 
either at the minor groove or between base pairs (intercalation).33,34  Minor groove 
binding generally involves hydrogen bonding interactions, so most compounds that bind 
in this manner possess several donor/acceptor groups in a curved arrangement to 
complement the shape of the DNA helix.  Intercalation is primarily hydrophobic in 
nature, and the best intercalators generally consist of fused aromatic rings capable of 
efficient π-overlap with nucleobase moieties.  Because hydrogen bonds tend to survive in 
the gas phase better than π-π interactions, a recurrent question in ESI-MS studies of DNA 
duplex behavior is whether these two binding modes can be distinguished with mass 
spectrometric data. 
 
6.3.2.1 Drug/Duplex Complexes Containing Intercalators 
Nogalamycin and daunomycin (structures given in Figure 6.1) are anthracycline 
antibiotics known to interact with duplex DNA by intercalation.33  Gas-phase complexes 
containing these drugs have been shown to mimic binding patterns expected in solution 
for intercalation between DNA base pairs, with the number of bound ligands being 
proportional to drug:DNA ratios.15,35  The electrospray mass spectrum for a solution 
containing equimolar concentrations of the 10 base pair duplex d(GCGAATTCGC)2 and 
nogalamycin (Nog) is shown in Figure 6.3A.  Intact drug:DNA complexes were observed 






Figure 6.3: ESI and CAD product ion spectra for complexes containing 
d(GCGAATTCGC)2 and nogalamycin:   (A)  full scan mass spectrum, (B)  
CAD of [ds + Nog]-4, 0.55V/ 30 ms, (C) CAD of [ds + Nog]-5, 0.55V/30 ms, 
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(The ion at m/z 1907 is attributed to [ds + 2 Nog]-4 rather than [ss + Nog]-2 based on the 
spacing of the associated sodium adduct peaks.)  The CAD spectrum for the 1:1 complex 
in the -4 charge state (Fig. 6.3B) shows the predominant loss of a neutral drug molecule, 
with a bare duplex ion remaining at m/z 1513 and no single-stranded species in evidence.  
In contrast, CAD of the [1:1]-5 complex produced intense [ss]-n and [ss + Nog]-n ions (n = 
2 or 3) as shown in Fig. 6.3C.  (The ion at m/z 1512 was assigned as [ss]-2 rather than 
[ds]-4 on the basis of MS3 experiments, which did not yield the Type II fragments that 
would have been expected based on MS/MS results in Fig. 6.2D.)  These species result 
from strand separation with retention of drug on one strand. Energy-resolved CAD 
experiments show that the [ss]-n ions form directly from the precursor and not from 
secondary loss of drug from [ss+ Nog]-n species, and duplex dissociation is therefore 
favored over drug ejection for the [1:1]-5 complex.  Strand separation produces less 
highly charged species, so the dramatic dependence of fragmentation on the initial charge 
state is likely a result of Coulombic effects.  CAD of the [2:1]-5 complex (Fig. 6.3D) gave 
the [ds + Nog]-4 ion as the major product.  This process entails charge reduction via 
ejection of the drug in deprotonated form, which indicates that Coulombic factors affect 
fragmentation at this stoichiometry as well.  The fact that strand separation was not 
observed suggests that the second nogalamycin molecule binds the duplex more weakly 
than the first. 
To explore the effect of oligonucleotide sequence, CAD spectra were acquired for 
1:1 complexes between nogalamycin and d(GCGCATGCGC)2, a duplex with slightly 
higher GC content.  CAD of the [ds + Nog]-4 complex with this new sequence (Fig. 6.4A) 
gave loss of neutral drug, as was observed for the original sequence in Fig. 6.3B.  




Figure 6.4: CAD product ion spectra for complexes containing d(GCGCATGCGC)2 
and nogalamycin: (A) [ds + Nog]-4, 0.55V/30 ms, (B) [ds + Nog]-5, 0.50V/ 
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species (Fig. 6.4B), in contrast with the results shown in Fig. 6.3C, in which strand 
separation was evident.  This indicates that a greater number of inter-strand hydrogen 
bonds can promote the drug ejection pathway over strand separation, as would be 
expected for duplexes containing greater GC content.  Conversely, greater AT content 
should promote strand separation over drug ejection, and results for complexes with 
nogalamycin and d(GCAAATTTGC)2 (not shown) provide some support for this.  CAD 
of the [ds + Nog]-5 precursor gave a spectrum similar to the one shown in Fig. 6.3C.  
CAD of the [ds + 2 Nog]-5 precursor (Figure 6.4C), however, produced a greater degree 
of strand separation than is evident in Fig. 6.3E for the complex with 
d(GCGAATTCGC)2.  While the mode of drug binding to these two duplexes may not be 
the same, intercalation and minor groove binding cannot be distinguished based on CAD 
spectra for drug/duplex complexes in high charge states (vide infra). 
Experiments conducted with daunomycin indicate that fragmentation pathways 
can also vary somewhat with the identity of the drug even when the nominal mode of 
binding (intercalation in this case) is the same.  The electrospray mass spectrum for a 
solution containing d(GCGAATTCGC)2 and daunomycin (Dn) is shown in Figure 6.5A, 
with the 1:1 and 1:2 duplex:daunomycin complexes labelled.  The product ion spectrum 
for the [ds + Dn]-4 complex (Fig. 6.5B) generally resembles the one obtained for the 
nogalamycin complex (Fig. 6.3B) in that ejection of neutral drug was the predominant 
process.  The [ds + Dn]-5 complex, like the [ds + Nog]-5 complex, produced significant 
strand separation (Fig. 6.5C vs. 6.3C).  (As in Fig. 6.3C, the ion at m/z 1512 was assigned 
as [ss]-2 rather than [ds]-4 on the basis of MS3 experiments.)  Collisional activation of the 
1:2 DNA:daunomycin complex in the -5 charge state (Fig. 6.5D) clearly leads to 
competition between dissociation pathways involving strand separation, neutral drug loss 






Figure 6.5: ESI and CAD product ion spectra for complexes containing 
d(GCGAATTCGC)2 and daunomycin:   (A)  full scan mass spectrum, (B)  
CAD of [ds + Dn]-4, 0.58V/30 ms, (C) CAD of [ds + Dn]-5, 0.53V/30 ms, 
and (D) CAD of [ds + 2 Dn]-5, 0.55V/30 ms. Parent ions are marked *. 
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daunomycin.  The differences apparent in Figs. 6.3D and 6.5D indicate that the observed 
fragmentation  pathways  reflect the  particular  intermolecular  interactions present in the 
complex, and that these interactions can vary for different drugs even when they are 
known to interact by the same general binding mode.  Some common elements emerge 
nonetheless from the dissociation of duplex/intercalator complexes.  The spectra in Figs. 
6.3-6.5 give little to no evidence of covalent dissociation, a process observed upon CAD 
of the duplexes alone, regardless of charge state, sequence, or the identity of the 
intercalator.  In addition, none of these spectra  exhibited a strong dependence on 
activation time and voltage (data not shown).  These observations correlate with the 
analysis presented by Gabelica and DePauw, which postulated time-independent non-
covalent fragmentation of gas-phase duplex/intercalator complexes.11  
 
6.3.2.2  Drug/Duplex Complexes Containing Minor Groove Binders 
To complement data obtained for duplex/intercalator complexes, dissociation 
experiments were also undertaken with a series of minor groove binding agents.  
Distamycin (Dist) is an antitumor antibiotic natural product which has been shown to 
bind the minor groove of B-DNA with an AT base pair specificity.36  This compound 
possesses the “classic” crescent-shaped structure common to many minor groove binders, 
which allows favorable non-covalent interactions between the molecule and DNA bases 
along the minor groove.  Studies investigating distamycin-DNA complexes via 
electrospray ionization mass spectrometry have been reported showing the generation of 
gas-phase complexes containing 1:1 and 1:2 DNA:distamycin stoichiometries,14,16,35 in 




Figure 6.6: ESI and CAD product ion spectra for complexes containing 
d(GCGAATTCGC)2 and distamycin:  (A)  full scan mass spectrum, (B)  
CAD of [ds + Dist]-4; 0.63V/30 ms, (C) CAD of [ds + Dist]-5, 0.55V/30 ms 
(D) CAD of [ds + 2 Dist]-4, 0.6V/30 ms and (E) CAD of [ds + 2 Dist]-5, 
0.50V/30 ms. Parent ions are marked *. 
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Figure 6.6A shows a representative mass spectrum for a solution containing 
equimolar   concentrations   of   d(GCGAATTCGC)2   and   distamycin   (Dist).    Ions 
corresponding to complexes of the type [ds + Dist]-n and [ds + 2 Dist]-n were observed in 
both  the  -5  and  -4  charge  states.   (The  peak  at  m/z  1754  is  attributed  primarily  to 
[ds + 2 Dist]-4 rather than [ss + Dist]-2 based on the spacing of the associated sodium 
adduct peaks.)  CAD of the [ds + Dist]-4 complex (Fig. 6.6B) produced a variety of Type 
II fragments (e.g. [ds – GH]-4, [ds – a1 + Dist]-4).  Little evidence of strand separation or 
drug loss was observed.  The CAD spectrum for the -5 charge state complex (Fig. 6.6B) 
shows a dramatic difference in dissociation pathway, with strand separation predominant 
over drug or base loss.  Relative to the intercalators, the lack of drug loss for either the –4 
or –5 charge states of the distamycin/duplex complexes may be attributed to the hydrogen 
bonding interactions between the amide nitrogens on the drug and the nucleobases 
exposed at the floor of the minor groove, and perhaps also to the strong gas-phase 
electrostatic interactions between the permanently-charged guanidinium group of 
distamycin and the DNA backbone phosphates.  The marked differences in dissociation 
pathways for these complexes once again illustrate the effect of Coulombic interactions 
upon complex stability.   
CAD spectra for the [ds + 2 Dist]-4 and [ds + 2 Dist]-5 species are shown in Fig. 
6.6D and E, respectively.  Like [ds + Dist]-4, [ds + 2 Dist]-4 gave Type II products of 
covalent dissociation almost exclusively (compare Figs. 6.6B and D), and like [ds + 
Dist]-5, [ds + 2 Dist]-5 underwent only strand separation (compare Figs. 6.6C and E).  
These results closely parallel the charge state-dependent trends obtained for the 1:1 
complexes.  The fact that little evidence of drug loss was observed for the 1:2 complexes 
indicates that the second distamycin molecule binds virtually as strongly as the first.  This 
contrasts with data for the nogalamycin complexes, where the [ds + 2 Nog]-5 precursor 
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dissociated primarily by ejection of deprotonated nogalamycin.  It is, however, consistent 
with the formation of a “head-to-tail” dimer in which both distamycin molecules bind via 
comparable interactions with the duplex; this binding mode has been observed in 
previous NMR studies.38 
Distamycin also formed 1:1 and 1:2 complexes with d(GCGCATGCGC)2 and 
d(GCAAATTTGC)2, and as in Fig. 6.6A the 1:2 stoichiometry was favored based on its 
greater signal intensity. The CAD spectrum of the [ds + Dist]-4 complex with 
d(GCAAATTTGC)2, acquired with an activation time of 30 ms, is shown in Fig. 6.7B.  
This precursor gave [ss]-2 and [ss + Dist]-2 fragments via strand separation in addition to 
several Type II fragments via covalent cleavage, again showing that the base composition 
of the DNA duplex influences the preferred dissociation pathways.  (In this case m/z 
1512 could not be distinguished as either [ss]-2 or [ds]-4 because as described above, CAD 
of [d(GCAAATTTGC)2]-4 gave only products deriving from cleavage of single-strands 
and no characteristic Type II fragments.)  Unlike the lower charge states of the 
duplex/intercalator species, however, [ds + drug]-4 parent ions for duplex/minor groove 
binder complexes gave fragmentation patterns that were strongly dependent on the 
activation conditions.  This is illustrated for the complex with d(GCAAATTTGC)2 by 
comparing Fig. 6.7B with Fig. 6.7A and C:  the relative intensity of the [ss]-2 and [ss + 
Dist]-2 ions decrease as activation time increases and activation voltage decreases.  This is 
consistent with the CAD results for the drug-free duplex species shown in Fig. 6.2C-E, 
and it also bears out the prediction that dissociation data for DNA/minor groove binder 
complexes  should be dependent on activation regime (and therefore activation time).11 
Figure 6.8 shows CAD spectra for [ds + drug]-4 parent species produced by ESI of 
d(GCGAATTCGC)2 and the minor groove binders netropsin, DAPI, and Hoechst 33342.  





Figure 6.7: CAD product ion spectra for [d(GCAAATTTGC)2 + Dist]
-4.  (A) 1.2V/3 ms, 
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Figure 6.8: CAD product ion spectra for [d(GCGAATTCGC)2 + drug]
-4 complexes with 
(A)  netropsin, 0.65V/30 ms, (B) DAPI, 0.63V/30 ms and (C) Hoechst 
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by products of covalent cleavage, like the spectrum obtained for the distamycin complex 
of this sequence (Fig. 6.6B).   For the complex with  Hoechst 33342, however, ejection of 
the neutral drug was a competitive process, as indicated by the presence of the [ds]-4 ion 
in Fig. 6.8C.    This result could indicate that Hoechst 33342 binds this duplex less avidly 
than the other drugs in the gas phase; its structure contains fewer hydrogen bond donors 
than distamycin and netropsin, and fewer charged groups than netropsin and DAPI.  
However, solution studies have prompted speculation that Hoechst 33258, a close analog 
of Hoechst 33342, may bind duplex DNA both in the minor groove and to a lesser extent 
by non-classical intercalation.39-42 The results presented above for nogalamycin and 
daunomycin shows that the drug ejection pathway is favored for duplex/intercalator 
complexes in low charge states, so the spectrum in Fig. 6.8C could also be interpreted as 
evidence of multiple binding modes for Hoechst 33342.  The proportion of drug ejection 
vs. covalent dissociation decreased as activation time increased and activation voltage 
decreased (data not shown), loss of drug remained a major process at long activation 
times. 
Norfloxacin belongs to the fluoroquinolone family of antibiotics, which exhibit 
potent antibacterial activity through the inhibition of DNA gyrase.43-48  The primary 
binding target for these compounds is thought to be the DNA substrate for gyrase rather 
than the protein itself, but the specific DNA binding mode for the fluoroquinolones 
remains controversial.  Recent spectroscopic and molecular modeling investigations 
suggest that norfloxacin may interact with duplex DNA by multiple binding modes, 
including both groove and non-classic intercalative interactions, and some evidence for a 
GC base pair preference has been reported.49-52  To our knowledge the gas-phase 
interactions between oligonucleotides and norfloxacin have not been studied.  ESI-MS 




Figure 6.9: ESI and CAD product ion spectra for complexes containing 
d(GCGAATTCGC)2 and norfloxacin:  (A)  full scan mass spectrum, (B)  
CAD of [ds + Nor]-4, 0.53V/30 ms and  (C) CAD of [ds + Nor]-5, 0.53V/30 































were interpreted in light of results obtained for the minor groove binding and 
intercalating drugs discussed above. 
The electrospray mass spectrum for solutions containing d(GCGAATTCGC)2 and 
norfloxacin is shown in Figure 6.9A.  Ions corresponding to -4 and  -5 charge state 
complexes containing from 1:1 to 3:1 norfloxacin:DNA ratios are detected, with a 
binding pattern and distribution reminiscent of gas-phase DNA-drug complexes 
containing intercalators as in Figs. 6.3A and 6.5A.  The CAD product ion spectra for the -
4 and -5 charge state 1:1 complexes (Fig. 6.9B and C) produce results similar to those 
observed for nogalamycin and daunomycin, namely preferential loss of one neutral drug 
from the -4 charge state parent ion, and strand dissociation/drug loss from the –5 charge 
state precursor.  These results do not strictly preclude interactions with the minor groove, 
but in comparison with results for minor groove binders, particularly distamycin, 
netropsin, and DAPI, they do seem to rule out a binding modes that might involve an 
extensive network of hydrogen bonds. 
 
6.4 CONCLUSIONS 
The results presented above demonstrate the dramatic effect of charge state upon 
the dissociation of gas-phase DNA-DNA and drug-DNA complexes.  Generally, duplex 
strand separation predominates for higher charge states.  This characteristic “unzipping” 
is likely due to complex destabilization caused by internal Coulombic repulsion, and was 
found to be relatively insensitive to activation time and voltage.  The DNA sequence 
and/or the structure of the drug can counteract this tendency to some extent, indicating 
that the phenomenon reflects the relative strength of both the DNA-DNA and drug-DNA 
interactions.  For lower charge states, ejection of either a neutral or deprotonated drug 
molecule predominated for DNA/intercalator complexes, and this was shown to be nearly 
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independent of activation time.  For complexes with minor groove binders, covalent 
cleavage was generally favored over drug ejection, although the competition between 
these processes was strongly dependent on activation time.  The dissociation pathways 
for the lower charge state complexes are probably more reflective of specific drug-DNA 
interactions because Coulombic effects are less marked for these precursors.  Thus, CAD 
analysis of the lower charge state complexes is more appropriate in evaluating gas-phase 
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Chapter 7:  Electrospray Ionization of Nucleic Acid Aptamer/Small 
Molecule Complexes for Screening Aptamer Selectivity 
7.1 INTRODUCTION 
Aptamers are nucleic acids (strands of DNA or RNA) that are capable of 
recognizing target molecules with high specificity and affinity.1-5  Aptamers are generally 
“unnatural” sequences, isolated not from biological sources but rather by in vitro 
selection from combinatorial libraries.1-7  The selection process typically begins with a 
large pool of DNA or RNA (1013-1015 randomized sequences), which is gradually 
reduced in complexity by multiple cycles of affinity chromatography and PCR 
amplification.  The sequences that survive this process can bind their target analytes with 
affinities (Kd) ranging from 10-5 to 10-13 M and discriminate between molecules that 
differ by as little as a single methyl group.3,4  Because of these recognition properties, 
aptamers can be employed as sensitive diagnostic agents,5 biomedical research tools,3,8 
and even as therapeutics.9  On a more fundamental level, aptamers readily lend 
themselves to structural analysis by NMR spectroscopy because of their modest size. 
Several three-dimensional binding motifs later found in biologically relevant systems 
were originally identified during structural characterization of aptamer/ligand 
interactions.4 
Electrospray ionization mass spectrometry (ESI-MS) has been used to assess 
binding stoichiometry and relative binding affinity in numerous molecular recognition 
processes, from cation/crown ether interactions10 to drug/receptor interactions. 11 12,13  
The electrospray process is gentle and can preserve, at least to some extent, the delicate 
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biomolecular architecture involved in many protein/nucleic acid,11,12,14 nucleic 
acid/nucleic acid, 12 and nucleic acid/ligand interactions,12,13 which suggests that 
aptamer/ligand interactions might survive as well.  If so, mass spectrometry could 
provide a tool for rapidly screening aptamer selectivity, and might possibly accelerate the 
process of identifying high-affinity sequences during selection.  Recently, a gas-phase 
complex between the transcription factor NF-kappaB and its RNA aptamer has been 
reported,15,16 illustrating that  aptamer interactions with large, pre-organized target 
molecules can be detected by ESI-MS.  To our knowledge, however, no such reports 
involving small molecule ligands have appeared.  We therefore selected several 
previously characterized aptamers that recognize small molecules as case studies for ESI-
MS analysis, including aptamers for tobramycin,17,18 adenosine triphosphate (ATP),19,20 
flavin mononucleotide (FMN),21-23 and theophylline.24-26  These receptors bind their 
targets with affinities ranging from 6 µM to 12 nM through specific intermolecular 
interactions that have been identified in independent structural studies.  ESI experiments 
were conducted for each aptamer in the presence of several ligands, and in some cases 
parallel solution assays were conducted to provide data for comparison.  Our results 
indicate that only limited correlations can be drawn between the gas- and solution-phase 




The 27-residue DNA aptamer that binds adenosine, AMP, and ATP (5’-
ACCTGGGGGAGTATTGCGGAGGAAGGT-3’)19 was purchased from Invitrogen 
(Carlsbad, CA).   RNA aptamers that bind tobramycin (5’-GGGACUUGGUUUA-
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GGUAAUGAGUCCCU-3’)18, FMN (5’-GGCGUGUAGGAUAUGCUUCGGCAGAA-
GGACACGCC-3’)22 and theophylline (5’-GGCGAUACCAGCCGAAAGGCCCUUG-
GCAGCGUC-3’) were chemically synthesized on an Expedite 8909 synthesizer (Perkin-
Elmer, Norwalk, CT) using standard RNA phosphoramidite reagents purchased from 
Glen Research (Sterling, VA).  Adenosine triphosphate (ATP) was purchased from 
Epicentre (Madison, WI), and all other ligands (structures given in Figure 7.1) were 
purchased from Sigma (St. Louis, MO).  Gentamicin (Sigma) was obtained  as a mixture 
of the C1, C2, and C2A variants and was used as received.  MnCl2 was purchased from 
Aldrich (Milwaukee, WI). 
 
7.2.2 Mass Spectrometry 
All mass spectrometry experiments were performed on an LCQ Duo  quadrupole 
ion trap mass spectrometer (ThermoQuest, San Jose, CA) using a heated capillary 
temperature of 80-90°C to minimize decomposition in the electrospray interface.  
Aptamer solutions contained 20 µM oligonucleotide and 50 mM ammonium acetate in 
10% isopropanol/water (ATP aptamer), or 2 µM oligonucleotide and 50 mM ammonium 
acetate in 30% isopropanol/water (tobramycin, FMN, and theophylline aptamers).  
Ligands (1-5 eq.) and/or divalent metal salts (2-5 eq.) were also added as appropriate.  
The final pH of these solutions was approximately 6.5.  Electrospray experiments were 
conducted in negative ion mode (-3.4 kV) by direct infusion (3 µl/min).  For experiments 
with tobramycin and other aminoglycosides, the usual fused silica infusion line was 
replaced with deactivated fused silica to prevent sample carryover.  Collision-activated 
dissociation (CAD) experiments were performed on selected precursors using activation 
voltages sufficient to reduce the parent ion intensity by 80-90%.  One to two hundred 



























































































































































tobramycin (467) bekanamycin (467)
adenosine (267) inosine (268)
3'-AMP (347)
5'-AMP (347) ATP (507) 5'-aminoadenosine (266)
FMN (456) riboflavin (376)
7,8-dimethylalloxazine (242)






Figure 7.1: Structures of ligands used in ESI-MS experiments.  Molecular weights (Da) 















7.2.3 Column Binding Assays 
Buffers used in selection experiments typically employ both monovalent and 
divalent metal salts (usually NaCl and MgCl2) at approximate concentrations of 100-300 
mM and 1-5 mM, respectively.  Such high concentrations of involatile salt strongly 
suppress ionization in electrospray experiments, however, and can also clog the sampling 
orifice of the mass spectrometer.  For this reason, the primary buffer salt used in the 
electrospray solutions was ammonium acetate, which is relatively volatile and therefore 
better tolerated in ESI-MS experiments.  Furthermore, when ESI mass spectra indicated 
that divalent metal salts were required to mediate aptamer/ligand binding (as indicated by 
the presence of aptamer/ligand complexes incorporating adventitious cations), MnCl2 was 
employed to provide aptamer/metal/ligand complexes with unambiguous m/z values.   
Aptamer/ligand binding is often quite sensitive to buffer conditions, however, and 
relatively minor changes in the composition and/or pH of the original selection buffer can 
reduce binding efficiency or possibly change relative binding affinities.  Ligand 
competition experiments were therefore conducted for both the ATP and FMN aptamers 
using a buffer containing 50 mM ammonium acetate and 5 mm MnCl2, which 
approximates the solution conditions used in the electrospray experiments. 
   
7.2.3.1 ATP Binding Assays 
Competition assays were conducted using the column binding procedure 
originally reported by Huizenga and Szostak.19  Briefly, the ATP aptamer was 
radiolabeled at the 5’ end using T4 polynucleotide kinase purchased from New England 
Biolabs (Beverly MA) and [γ -32P] ATP (7000 ci/mmol) purchased from MP Biomedicals 
(Aurora, OH).  After gel purification, 40-60 pmol of γ-labeled ATP aptamer was 
denatured at 72°C (2 min.), then cooled to room temperature (20-30 min.) and incubated 
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at room temperature (30 min.) with ATP agarose purchased from Sigma (St. Louis, MO).  
The pre-equilibrated agarose was then loaded onto a chromatography column purchased 
from Bio-Rad Laboratories (Hercules, CA) and washed with three column volumes of 
binding buffer.  In these studies the standard buffer (300 mM NaCl, 5 mM MgCl2, 20 
mM Tris, pH 7.6)19 was replaced with a buffer comprised of 50 mM ammonium acetate, 
5 mM MnCl2 at pH 6.5.  The DNA aptamer was then eluted with 1-3 mM ligand 
(adenosine, inosine, 3’-AMP, 5’-AMP, ATP, or 5’-aminoadenosine) in binding buffer.  
The amount of DNA retained on the column and in the wash and elute volumes was 
determined by scintillation counting, and the percentage of eluted DNA aptamer was 
determined.      
 
7.2.3.2 FMN Binding Assays 
Competition assays were conducted as previously described.21  FMN-agarose was 
prepared by conjugating FMN with cyanogen bromide-activated agarose (Sigma, St. 
Louis MO) at 5 mg/mL.  The RNA aptamer was radiolabeled at the 5’ end using T4 
polynucleotide kinase purchased from New England Biolabs (Beverly, MA) and [γ -32P] 
ATP 7000ci/mmol purchased from MP Biomedicals (Aurora, OH).  Following gel 
purification, 40-60pmol of γ-labeled FMN aptamer was denatured at 72°C (2 min.), then 
cooled to room temperature (20-30 min.) and incubated at room temperature with FMN 
agarose (30 min.).  The pre-equilibrated agarose was then loaded onto a chromatography 
column purchased from Bio-Rad Laboratories (Hercules CA) and washed with three 
column volumes of binding buffer.  In these studies the standard buffer (250 mM NaCl, 5 
mM MgCl2, 50 mM Tris, pH 7.6)21 was replaced with a buffer comprised of 50 mM 
ammonium acetate, 5 mM MnCl2 at pH 6.5.  The RNA aptamer was then eluted with 1-3 
mM ligand (riboflavin, FMN, and 7,8-dimethylalloxazine) in binding buffer.   The 
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amount of RNA retained on the column and in the wash and elute volumes was 
determined by scintillation counting, and the percentage of eluted RNA aptamer was 
determined.      
  
7.3 RESULTS AND DISCUSSION  
 To evaluate mass spectrometry as a tool for screening molecular 
recognition and discrimination by DNA and RNA aptamers, ESI-MS experiments and 
were conducted for each of four previously characterized aptamers in the presence of 
several ligands.  The relative binding affinities determined by ESI-MS were compared to 
trends established by traditional solution methods.  For the ATP and FMN aptamers, 
solution binding trends were determined experimentally, and for the tobramycin and 
theophylline aptamers trends reported in previous literature17,18,24 were used for 
comparison.  In some cases collision-activated dissociation (CAD) was utilized to further 
assess the relative stability of the observed gas-phase complexes. 
 
7.3.1 Tobramycin Aptamer/Ligand Interactions 
At pH 7.4, the 27-residue RNA aptamer for tobramycin18  binds one ligand in a 
high-affinity site (Kd = 12 nM) and can also bind a second tobramycin molecule in a 
lower affinity site (13 µM).17  The related aminoglycoside bekanamycin binds with 
similar affinity, but gentamicin, which has a different pattern of substituents on its two 
sugar rings, binds much less efficiently.18  The 1:1 complex with tobramycin has been 
studied by NMR at pH 6.8,18 and the resulting three-dimensional structure (PDB code 
2TOB)27 reveals a distorted hairpin comprised of a 6 base-pair stem and a 14-residue loop 
region, which provides a deep pocket for ligand binding.  The size of the pocket and a 
network of hydrogen bonds between protonated amino groups on the ligand and 
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backbone phosphates on the aptamer provide the basis for high affinity binding by 
tobramycin and bekanamycin, but preclude effective interactions with gentamicin. 
 Full scan ESI-MS spectra acquired for solutions containing this aptamer 
and various aminoglycosides are shown in Figure 7.2.  Under the conditions used in these 
experiments (50 mM ammonium acetate, 30% isopropanol/water) the aptamer produced 
ions at m/z 1443 and 1732, corresponding to the –6 and –5 charge states (Fig. 7.2A).  In 
the presence of one equivalent of either tobramycin or bekanamycin, the dominant 
species were 1:1 aptamer:ligand complexes, with 1:2 complexes also visible at much 
lower intensity (Fig. 7.2B and C).  Signals for free RNA were barely detectable in these 
spectra.  In the presence of gentamicin, however, peaks for free RNA were dominant and 
peaks for 1:1 complexes were relatively insignificant (Fig. 7.2D).  These results correlate 
exactly with the known trend in solution binding18 and therefore indicate that the gas-
phase data reflect specific binding behavior.  Titration of the aptamer with increasing 
amounts of tobramycin demonstrated that 1:1 and 1:2 aptamer:ligand complexes form 
sequentially (Fig. 7.3), which is consistent with the wide difference in their solution 
binding constants and provides further evidence of the specific nature of the interactions 
reflected in the MS data. 
CAD experiments were performed to assess the kinetic stability of these 
complexes, and representative results are shown in Figure 7.4.  The –5 charge state of the 
1:1 complex with tobramycin dissociated by covalent cleavage (loss of nucleobase 
moieties or H2O) rather than non-covalent loss of ligand (Fig. 7.4A).  Competition 
between covalent and non-covalent cleavage processes has been observed in previous 
CAD studies of both DNA duplexes and duplex/drug complexes in the quadrupole ion 
trap,28-31 and both the activation conditions30 and initial charge state of the precursor31 
have  been  shown  to  affect  this  competition.  In experiments designed to promote non- 
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Figure 7.2: ESI spectra for samples containing the tobramycin aptamer (RNA).  A) 
Tobramycin aptamer, B) aptamer + 1 eq. tobramycin, C) aptamer + 1 eq. 
bekanamycin, and D) aptamer + 1 eq. gentamicin (mixture of isomers).  All 
solutions contained 2 µM RNA and 50 mM NH4OAc in 30% IPA/H2O. 
 
 



























































Figure 7.3: Titration of tobramycin aptamer (2 µM) with tobramycin.  Plot of 














































Figure 7.4: CAD of non-covalent complexes with the tobramycin aptamer (-5 charge 
states). (A) 1:1 and (B) 1:2 complexes with tobramycin, (C) 1:1 complex 
with gentamicin C2.  Parent ions are marked (*); no significant fragments 
were observed below m/z 1600. 
 
 




























covalent loss of ligand (use of the –6 charge state precursor, short activation times/high 
activation voltages), the 1:1 aptamer:tobramycin complex still dissociated exclusively by 
covalent cleavage.  The dissociation behavior of the 1:1 aptamer:bekanamycin complexes 
was essentially the same (data not shown).  For both of these complexes, a network of 
hydrogen bonds confers high affinity binding, and because such interactions are generally 
stronger in the gas phase than in solution,11,14 the energy involved in disrupting this 
network of interactions exceeded the energetic cost of covalent base loss.   
In solution, the second tobramycin binds much less strongly (13 mM vs. 12 nM), 
and the 1:1 complex with gentamicin is also known to be a relatively low-affinity 
interaction (although a specific binding constant has not been reported).  CAD mass 
spectra acquired for the –5 charge state precursors of both the 1:2 aptamer:tobramycin 
complex and the 1:1 aptamer:gentamicin C2 complex (shown in Fig. 7.4B and C) 
illustrate that these complexes dissociated exclusively by covalent cleavage just like the 
high-affinity 1:1 aptamer:tobramycin complex (Fig. 7.4A).  These results were also 
independent of both the initial charge state of the complex and the activation time/voltage 
(data not shown), which indicates that electrostatic and/or hydrogen bonding interactions 
maintain the intermolecular contacts in these complexes as well.  Because the CAD 
spectra reflect the nature of the gas-phase aptamer/ligand interactions rather than the 
solution binding constants, full scan ESI mass spectra were more reliable than the CAD 
mass spectra for determining the relative binding affinities of this receptor/ligand system. 
 
7.3.2 ATP Aptamer/Ligand Interactions 
 The 27-residue DNA aptamer selected to bind ATP also binds the related 
molecules AMP and adenosine with approximately equal affinity (Kd ~ 6 µM).19  An 
NMR study conducted at pH 6.3 showed that  these molecules bind with a characteristic 
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1:2 aptamer:ligand stoichiometry, probably as a consequence of the high ligand load and 
long covalent linker used during affinity chromatography in the original selection 
experiments.20  In the 1:2 aptamer:AMP complex (PDB code 1AW4), the aptamer adopts 
a hairpin conformation, with Watson-Crick base-pairing at the stem and an internal 
mismatch region that provides two sites for ligand binding.20  Each AMP molecule 
intercalates between a reversed-Hoogsteen mismatch and the adenine partner of a sheared 
G•A mismatch, and also forms hydrogen bonds with an internal guanine residue.  These 
recognition motifs discriminate effectively against GTP, UTP, and CMP, as well as the 
purine analog inosine.19   
Several ESI mass spectra acquired for solutions containing this aptamer are 
shown in Figure 7.5.  Solutions containing only the aptamer produced ions at m/z 1413 
and 1696, corresponding to the –6 and –5 charge states; the spectral region around the –5 
charge state is shown in Fig. 7.5A.  A solution containing the aptamer and two 
equivalents of adenosine produced 1:1 and 1:2 aptamer:ligand complexes at m/z 1750 
and 1803 (Fig. 7.5B).  Titration experiments (not shown) demonstrated that these species 
do not form in stepwise fashion, which confirms that the two ligand molecules bind 
cooperatively in agreement with the known solution behavior.20    
Satellite peaks at m/z 1757 and 1809 are also visible in Fig. 7.5B, and these were 
tentatively assigned as aptamer/K+/ligand or aptamer/Ca+2/ligand complexes.  The 
spontaneous incorporation of adventitious metals indicates that efficient ATP 
aptamer/adenosine binding may require the presence of metal cations to ensure proper 
DNA folding.  In an attempt to facilitate ligand binding, two equivalents of divalent metal 
salt (MnCl2) were added to the aptamer/adenosine solutions, and upon electrospray 
ionization these solutions produced 1:1 and 1:2 aptamer:metal adducts, as well as 1:1:1 








Figure 7.5: ESI spectra for samples containing the ATP aptamer (DNA).  A) ATP 
aptamer, B) aptamer + 2 eq. adenosine, C) aptamer + 2 eq. MnCl2 and D) 
aptamer + 2 eq. adenosine, 2 eq. MnCl2.  Only the spectral region containing 
the -5 charge states is shown.  Complexes with adventitious metal ions (K+ 
or Ca+2) are marked *.  All solutions contained 20 µM DNA and 50 mM 
NH4OAc in 10% IPA/H2O. 
 




















































bound aptamer did not appear to increase with the addition of metal cations, however:  
the peak intensities for the aptamer:metal:ligand complexes in Fig. 7.5D were roughly the 
same as the peak intensities for the aptamer:ligand complexes in Fig. 7.5B.  Annealing 
the samples prior to ESI analysis did not increase the signal intensity of the complexes, 
nor did the addition of excess metal or excess ligand (up to 1:16:2 and 1:2:16 
aptamer:metal:adenosine ratios).  A possible explanation for these results arose on 
examination of the mass spectrum for a solution containing aptamer and Mn+2 but no 
added ligand, shown in Fig. 7.5C.  Here the [DNA]-5 and [DNA + Mn+2]-5 ions have 
nearly the same signal intensity.  In Fig. 7.5D, however, the [DNA + Mn+2]-5 ion is much 
more intense than the [DNA]-5 ion, and this change in peak ratio must be due to the 
presence of adenosine in the solution.  This led to the speculation that  the [DNA + 
Mn+2]-5 ion in Fig. 7.5D might arise from both association of the free aptamer with Mn+2 
as well as dissociation of the aptamer/metal/ligand complexes during the electrospray 
process.  Each ligand interacts with the aptamer through the combination of π-stacking 
and two hydrogen bonds, and it seems intuitive that these interactions would be 
weakened in the gas phase because the stabilizing contribution of the hydrophobic 
interactions would be lost.   
Some experimental evidence for the limited gas-phase stability of these 
complexes was found in follow-up experiments.  In ESI spectra collected at a heated 
capillary temperature of 110°C, the 1:1:1 and 1:1:2 complexes were virtually 
undetectable, demonstrating that these species quite susceptible to thermal 
decomposition.  Furthermore, in the presence of excess metal or ligand the 1:1:1 complex 
in Fig. 7.5D remained visible in ESI-MS spectra of aptamer/metal/adenosine solutions at 
approximately the same relative intensity as the 1:1:2 complex.  As noted above, two 
adenosine molecules bind this aptamer cooperatively in solution, i.e. without a discrete 
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intermediate at the 1:1:1 stoichiometry. 20  It therefore seems unlikely that the 1:1:1 
complex seen in Fig. 7.5D represents an intermediate in an associative process and is 
instead a decomposition product deriving from the 1:1:2 complex. 
Additional evidence of low gas-phase stability for some ATP aptamer/ligand 
complexes was also seen in ligand discrimination experiments conducted with adenosine, 
inosine, 3’-AMP, 5’-AMP, ATP, and 5’-aminoadenosine.   ESI-MS spectra acquired for 
six solutions containing the ATP aptamer, two equivalents of Mn+2 and two equivalents 
of one of these six ligands are shown in Fig. 7.6A-F.  The apparent trend in relative 
binding affinity, as indicated by signal intensities for intact aptamer/metal/ligand 
complexes, decreases in the order 5’-aminoadenosine >> adenosine > 5’-AMP, ATP > 
3’-AMP, inosine.  Column binding assays were performed using ammonium 
acetate/MnCl2 buffer as described above to provide solution data for comparison.  The 
results, shown in Figure 7.7, indicate a solution binding trend of ATP, 5’-AMP, 5’-
aminoadenosine > adenosine > 3’-AMP, inosine, which does not completely agree with 
the trend in signal intensity for the intact gas-phase complexes.  The gas-phase trend does 
make sense, however, when both solution affinity and ligand polarity (i.e. charge 
character in solution at the experimental pH of 6.5) are taken into account.  For example, 
the data in Fig. 7.7B indicate that the aptamer binds 5’-aminoadenosine efficiently in the 
electrospray buffer.  At pH 6.5, this ligand carries a formal positive charge on the 5’-
amine group.  The intense signals for gas-phase aptamer/Mn+2/5’-aminoadenosine 
complexes were therefore generated in solution by high-affinity recognition and 
preserved in the gas phase by dipolar and/or electrostatic interactions between the 
negatively charged aptamer and the positively charged ligand.  (This interpretation also 
explains the observation why the 1:1:2 stoichiometry clearly predominates in Fig. 7.6F.)  
Adenosine  binds  well  as  a  neutral  molecule  in  solution  (Fig. 7.7)  but  produces less  
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Figure 7.6: ESI spectra for the ATP aptamer (DNA), 2 eq. MnCl2 and 2 eq. ligand.  A) 
adenosine, B) inosine, C) 3’-AMP, D) 5’-AMP, E) ATP, and F) 5’-
aminoadenosine. Only the spectral region containing the -5 charge states is 



































































Figure 7.7: Column binding assays for ATP aptamer binding.  Percentage of aptamer 
















































intense gas-phase complexes than 5’-aminoadenosine (Fig. 7.6A vs. F) because it lacks 
the extra stabilization provided by the additional amine group.  Both 5’-AMP and ATP 
carry formal negative charges in aqueous solution at pH 6.5, so while the aptamer binds 
these ligands efficiently in solution, Coulombic repulsion destabilizes the interactions in 
the gas phase and greatly suppresses signal intensity for the intact complexes (Fig. 7.6D 
and E).  The fact that the aptamer apparently prefers to bind ATP in the presence of two 
Mn+2 cations (Fig. 7.6D) is likely another consequence of the overall charge of the ligand. 
It is interesting to note, however, that the solution results roughly correlate with 
the trend in signal intensity patterns in the spectral region between m/z 1696 and 1730 
(corresponding to the free aptamer and its Mn+2 complexes).  For ESI spectra acquired in 
the presence of ligands that bind weakly in solution (inosine, Fig. 7.6B and 3’-AMP, Fig. 
7.6C), the [DNA]-5 and [DNA + Mn+2]-5 ions have nearly the same signal intensity, as can 
be seen in Fig. 7.5C for a solution containing no added ligand.  In contrast, ESI spectra 
acquired for the ligands that bind strongly in solution (adenosine, 5’-AMP, ATP, and 5’-
aminoadenosine, Fig. 7.6A and D-F), the [DNA]-5 ion is less intense than the [DNA + 
Mn+2]-5 ions (alone and in combination with related ions at higher metal:aptamer 
stoichiometries).  This suggests that when aptamer/ligand binding interactions are metal 
mediated, differences in the metal adduction patterns around signals for the free aptamer 
can be diagnostic of solution interactions, regardless of whether intact complexes are 
directly observed. 
 
7.3.3 FMN Aptamer/Ligand Interactions 
 The 35-residue RNA aptamer for FMN binds its cognate ligand and the 
related compound 7,8-dimethylalloxazine with 500 nM affinity.21  Structural studies of 
the 1:1 aptamer:FMN complex (PDB code 1FMN) have shown that the FMN aptamer, 
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like the ATP aptamer, adopts a hairpin-like conformation and provides a ligand binding 
pocket in an internal mismatch region.22  The  ligand intercalates between a G•U•A base 
triple and a G•G mismatch and also forms hydrogen bonds with the Hoogsteen edge of 
an internal adenine residue.  The intermolecular interactions involved in this system, like 
the ATP aptamer system, therefore combine both dipole/dipole and hydrophobic 
interactions to achieve complex stability.  A strict requirement for the presence of 
divalent metal cations has been noted.22 
ESI mass spectra acquired for this aptamer are shown in Figure 7.8.  The aptamer 
alone produced a strong signal at m/z 1889, corresponding to the –6 charge state, along 
with a weaker signal at m/z 1619 for the –7 charge state.  The spectral region around the 
–6 charge state is shown in Fig. 7.8A.  Initial ligand binding experiments with this 
aptamer were conducted using riboflavin, a close analog of FMN.  ESI-MS of solutions 
containing the aptamer and 5 equivalents of riboflavin  produced an ion at m/z 1958  that 
was tentatively assigned as a 1:1:1 complex between the aptamer, adventitious K+ or 
Ca+2, and riboflavin (Fig. 7.8B).  These results were entirely consistent with the behavior 
of this aptamer in solution experiments.22  Added MnCl2 (5 eq.) produced the analogous 
aptamer/Mn+2/riboflavin complex in somewhat greater signal intensity as shown in Fig. 
7.8D.  The [RNA + Mn+2]-6/[RNA]-6 peak intensity ratio was somewhat higher when both 
Mn+2 and riboflavin were present in solution than when only Mn+2 was present (Fig. 7.8D 
vs. C).  As noted in experiments with the ATP system, this shift in the distribution of free 
vs. metallated aptamer indicates that some degree of gas-phase instability affects 
noncovalent ligand binding interactions of the FMN aptamer.  Such parallel results for 
the ATP and FMN aptamers make sense given that they bind their target ligands using 
similar recognition motifs (intercalation anchored by hydrogen bonds inside the binding 
cleft). 
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Figure 7.8 ESI spectra for solutions containing the FMN aptamer (RNA).  A) FMN 
aptamer, B) aptamer + 5 eq. riboflavin, C) aptamer + 5 eq. MnCl2, and D) 
aptamer + 5 eq. riboflavin, 5 eq. MnCl2.  Only the region containing the -6 
charge statesis shown.  All solutions contained 2 µM aptamer and 50 mM 
























































ESI mass spectra for the FMN aptamer in the presence of Mn+2 and riboflavin, 
FMN, and 7,8-dimethylalloxazine are shown in Figure 7.9A-C, respectively.  The 
solution containing FMN produced a weak signal for the 1:1:1 aptamer:Mn+2:ligand 
complex, as well as an [RNA + Mn+2]-6/[RNA]-6 peak intensity ratio that, in comparison 
to the data shown in Fig. 7.8C, suggests that significant decomposition of the complex 
has occurred in the gas phase.  In light of the results obtained in the ATP aptamer system 
for negatively charged ligands, these results were not surprising because like 5’-AMP and 
ATP, FMN would have been deprotonated in the electrospray solution.  The lack of 
stable gas-phase complexes containing 7,8-dimethylalloxazine (Fig. 7.9C) was 
unexpected, however, because this is a neutral ligand reported to bind the aptamer with 
high affinity in solution.21  Column binding experiments using ammonium acetate buffer 
confirmed that riboflavin and 7,8-dimethylalloxazine bind with equal affinity in the 
electrospray solvent (data not shown).  The [RNA + Mn+2]-6/ [RNA]-6 peak intensity ratio 
in  Fig. 7.9C is suggestive of gas-phase decomposition, but Coulombic effects must be 
ruled out as an underlying cause in this case.  This ligand lacks the glycerol side chain of 
riboflavin, and it may be that this side chain interacts with the aptamer and provides 
additional stability for the gas phase aptamer/Mn+2/riboflavin complex.  (Interactions 
between the phosphoglycerol side chain of FMN and the RNA backbone have been 
postulated based on molecular modeling studies of the FMN aptamer/FMN complex.23)  
Without these additional interactions, intact complexes between the aptamer and 7,8-
dimethylalloxazine may be too weak to survive in the gas phase.  As for the ATP system, 
then, results obtained by ESI-MS do not accurately reflect solution trends for the FMN 
aptamer. 
A CAD mass spectrum acquired for the 1:1:1 aptamer:Mn+2:riboflavin complex in 
the –6 charge state (Fig. 7.10)  showed that this  precursor  dissociates exclusively by loss 
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Figure 7.9: ESI spectra for the FMN aptamer + 5 eq. MnCl2, 5 eq. ligand.  A) 
Riboflavin, B) FMN, and C) 7,8-dimethylalloxazine.  Only the region 
containing the -6 charge states is shown.  All solutions contained 2 µM 














































of ligand.  The binding constant for this complex is approximately 500 nM and is due to 
the combined influence of at least two ligand-aptamer hydrogen bonds and hydrophobic 
interactions.  The binding constant for the 1:2 tobramycin aptamer:tobramycin 
interaction, which is maintained by hydrogen bonding, is 13 µM, and CAD of this 
complex dissociated exclusively by covalent cleavage with no apparent loss of ligand.  
Taken in conjunction, these results indicate that during collisional activation, the type of 
interactions maintaining intermolecular interaction dictate the observed fragmentation 
pathways, and that the observed fragmentation pathways do not necessarily correlate with 
solution Kd. 
 
7.3.4 Theophylline Aptamer/Ligand Interactions 
The 33-residue theophylline aptamer (RNA) binds its target ligand with 300 nM 
affinity and, in a striking example of the ligand specificity that can be achieved with 
aptamers, can discriminate for theophylline vs. the closely related compound caffeine by 
a factor of ~ 10,000.24  An NMR study of the 1:1 aptamer:theophylline complex (PDB 
code 1EHT) at pH 6.8 showed that hydrogen bonds between the ligand, one cytidine 
residue and one uridine residue form a base triple that interacts via π-stacking with 
A•C•G and U•U•A base triples above and below.25  Divalent metal cations (Mg+2, Co+2 
or Mn+2) are required to fold the RNA backbone properly.24,26 
A series of ESI mass spectra acquired for solutions containing this RNA are 
shown in Figure 7.11 and illustrate that, much like the ATP and FMN systems, 
aptamer/ligand interactions exhibit poor gas-phase stability here as well.  For the aptamer 
alone the dominant ion was the –6 charge state at m/z 1769 (Fig. 7.11A), and in the 
presence of a moderate excess of MnCl2 (5 eq.) the 1:1 aptamer:Mn+2 ion became visible 







Figure 7.10: CAD of 1:1:1 complexes with the FMN aptamer, Mn+2, and riboflavin in the 
























Figure 7.11: ESI spectra for solutions containing the theophylline aptamer (RNA).  A) 
Theophylline aptamer, B) aptamer + 5 eq. MnCl2, C) aptamer + 5 eq. 
MnCl2, 5 eq. theophylline, D) aptamer + 5 eq. MnCl2, 5 eq. 1-
methylxanthine, E) aptamer + 5 eq. MnCl2, 5 eq. theobromine.  Only the 
region containing the -6 charge states is shown.  All solutions contained 2 








































aptamer + MnCl2, 1-methylxanthine
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produce intact aptamer/ligand complexes, however (Fig. 7.11C).  In this system column 
binding experiments were not conducted to verify that aptamer/ligand binding occurs in 
the electrospray buffer.  However, the intensity of the [RNA + Mn+2]-6 ion is greater in 
Fig. 7.11C than in Fig. 7.11B, which may be diagnostic of solution interactions as noted 
in the interpretation of MS data acquired for the ATP and FMN aptamers.  Furthermore, 
the relative intensity of the [RNA + Mn+2]-6 ion decreases for solutions containing 
theophylline, 1-methylxanthine, and theobromine (Figs. 7.11C-E), and this trend 
correlates exactly with the reported solution binding affinities of these compounds.24  
These observations support the notion that the gas-phase stability of these aptamer/ligand 
complexes is compromised because the π-stacking forces that contribute so much 
stability in solution lose potency in vacuo. 
 
7.4 CONCLUSIONS 
Electrospray ionization mass spectrometry (ESI-MS) has been used to assess 
molecular recognition of small molecule ligands by nucleic acid aptamers for tobramycin, 
ATP, FMN, and theophylline.  The overall results indicate that the gas-phase behavior of 
aptamer/ligand complexes correlates with solution behavior in only some respects.  The 
binding stoichiometry and relative binding affinities determined by ESI-MS for the 
tobramycin aptamer, which interacts with its cognate ligand through hydrogen bonding 
interactions, accurately reflected the known solution behavior.  Results for the ATP, 
FMN, and theophylline aptamers, all of which recognize ligands via both hydrogen 
bonding and hydrophobic interactions, were more problematic.  For these systems, the 
metal dependence of ligand binding in solution was accurately reflected in the mass 
spectral data.  However, Coulombic effects deriving from ligand polarity/charge 
character stabilized some high-affinity aptamer/ligand complexes and destabilized others, 
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and complexes with a greater number of intermolecular hydrogen bonds exhibited greater 
gas-phase stability even in cases when solution binding affinities were equivalent.  Both 
factors precluded accurate determination of relative binding affinities from ESI-MS 
spectra.  This indicates that complementary techniques may be required to fully assess 
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Chapter 8:  Conclusion 
Over the last two decades mass spectrometry has gained extraordinary 
prominence in the study of biological macromolecules.  The initial (and probably most 
obvious) applications of MS in protein and nucleic acid analysis involved analyte 
identification through sequence determination, and although MS already competes well 
with alternative sequencing techniques such efforts still attract sustained interest.  
Chapters 3 and 4 of this work describe experiments conducted to characterize new or 
under-utilized fragmentation methods (MSAD and IRMPD) for biopolymer sequencing.  
These studies illustrate that different fragmentation methods can produce different 
information because of key details about the ion activation process, but they also show 
that alternative dissociation methods can nonetheless be effective and sometimes 
advantageous for protein and nucleic acid sequence determination.  A thorough 
evaluation of such methods makes it possible to fully exploit the range of options 
available for MS sequencing experiments. 
 Mass spectrometry can also be used probe the higher order structure and function 
of biopolymers by examination of their non-covalent associations.  Chapters 5, 6 and 7 
presented results obtained from mass spectrometric studies of nucleic acid complexes, 
and the results make it clear that the specific intermolecular interactions can be reflected 
in mass spectrometric data.  Substantial questions remain about the use of gas-phase 
measurements to draw conclusions about solution-phase structure, however, so a 
thorough understanding of the impact of different experimental variables is of paramount 
importance.  Chapters 5 and 6 illustrated that initial charge state can strongly influence 
 163
gas-phase fragmentation patterns, which highlights choice of precursor ion as a major 
consideration in designing dissociation experiments to study biomolecular interactions.  
In Chapter 7, Coulombic effects emerged as a critical factor controlling which species 
survive and can be studied in the gas phase, a result that suggests that MS is not 
universally applicable to the study of all non-covalent complexes. 
 Collectively, these studies supply new information on the gas-phase stability and 
dissociation tendencies of proteins, nucleic acids, and nucleic acid/small molecule 
complexes, and the results point the way to improved strategies for the identification and 
characterization of biopolymers that fully exploit the rapid, sensitive nature of mass 
spectrometric analysis.  Yet they also point to particular problems and limitations that 
should be addressed in future MS research.  At present mass spectrometry cannot provide 
routine de novo sequencing of large biopolymers, and new dissociation techniques and 
analytical strategies will be required to achieve this goal.  In addition, while even the 
most rudimentary biochemistry textbooks stress the importance of tertiary and quaternary 
structure on the function of proteins and nucleic acids in solution, very little is known 
about the conformation of these molecules in the gas phase.  Further growth and 
refinement in the use of ion mobility and other techniques that evaluate conformation will 
produce new information on gas-phase structure, which should not only provide new 
insight on folding patterns and dynamics observed in solution but should also provide a 
more detailed framework for analysis of non-covalent interactions that are preserved in 
the gas phase.  Continued development in areas such as these should enhance the overall 
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